



(11) (21) (C) **2,200,069**
(86) 1995/07/20
(87) 1996/03/21
(45) 2000/09/26

(72) LITTLE, Roger G., II, US

(72) LIM, Edward, US

(72) FADEM, Mitchell B., US

(73) XOMA CORPORATION, US

(51) Int.Cl.⁶ C07K 14/47, A61K 38/17, A61L 2/16, A61K 38/10, C07K 7/08,
A61K 38/08, C07K 7/06

(30) 1994/09/15 (08/306,473) US

(30) 1995/01/13 (08/372,105) US

(54) **PEPTIDES ANTIFONGIQUES**

(54) **ANTI-FUNGAL PEPTIDES**

(57) La présente invention se rapporte en général à des peptides antifongiques dérivés du Domaine III ou basés sur le Domaine III (acides aminés 142-169) de la protéine augmentant le pouvoir bactéricide et la perméabilité, et aux utilisations thérapeutiques de ces peptides. Les peptides mentionnés possèdent tous sept à douze acides aminés et comprennent une séquence de base (LIQL, IQLF, WLIQL, LIQLF et WLQLF) et au moins un acide aminé à caractère basique dans les régions terminales. Ces peptides sont soit linéaires, soit cycliques.

(57) The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and therapeutic uses of such peptides. The mentioned peptides all have from seven to twelve amino acids and comprise a core sequence of LIQL, IQLF, WLIQL, LIQLF and WLQLF and one or more basic amino acids in the terminal regions. Peptides are either linear or cyclic.





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, A61K 38/17	A1	(11) International Publication Number: WO 96/08509 (43) International Publication Date: 21 March 1996 (21.03.96)
(21) International Application Number: PCT/US95/09262 (22) International Filing Date: 20 July 1995 (20.07.95) (30) Priority Data: 08/306,473 15 September 1994 (15.09.94) US 08/372,105 13 January 1995 (13.01.95) US (71) Applicant: XOMA CORPORATION [US/US]; 2910 Seventh Street, Berkeley, CA 94710 (US). (72) Inventors: LITTLE, Roger, G., II; 620 Rose Drive, Benicia, CA 94510 (US). LIM, Edward; 1480 Creekside Drive #A-302, Walnut Creek, CA 94596 (US). FADEM, Mitchell, B.; 716 Colusa Avenue, Berkeley, CA 94707 (US). (74) Agent: BORUN, Michael, F.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 S. Wacker Drive, Chicago, IL 60606-6402 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). 2 2 0 0 0 6 9 Published <i>With international search report.</i>
(54) Title: ANTI-FUNGAL PEPTIDES (57) Abstract The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and therapeutic uses of such peptides. The mentioned peptides all have from seven to twelve amino acids and comprise a core sequence of LIQL, IQLF, WLIQL, LIQLF and WLQLF and one or more basic amino acids in the terminal regions. Peptides are either linear or cyclic.		

BACKGROUND OF THE INVENTION

The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and therapeutic uses of such peptides.

BPI is a protein isolated from the granules of mammalian polymorphonuclear leukocytes (PMNs or neutrophils), which are blood cells essential in the defense against invading microorganisms. Human BPI protein has been isolated from PMNs by acid extraction combined with either ion exchange chromatography [Elsbach, *J. Biol. Chem.*, 254:11000 (1979)] or *E. coli* affinity chromatography [Weiss, et al., *Blood*, 69:652 (1987)]. BPI obtained in such a manner is referred to herein as natural BPI and has been shown to have potent bactericidal activity against a broad spectrum of gram-negative bacteria. The molecular weight of human BPI is approximately 55,000 daltons (55 kD). The amino acid sequence of the entire human BPI protein and the nucleic acid sequence of DNA encoding the protein have been

reported in Figure 1 of Gray et al., *J. Biol. Chem.*, 264:9505 (1989). The Gray et al. DNA and amino acid sequences are set out in SEQ ID NOS: 205 and 206 hereto.

BPI is a strongly cationic protein. The N-terminal half of BPI accounts for the high net positive charge; the C-terminal half of the molecule has a net charge of -3. [Elsbach and Weiss (1981), *supra*.] A proteolytic N-terminal fragment of BPI having a molecular weight of about 25 kD has an amphipathic character, containing alternating hydrophobic and hydrophilic regions. This N-terminal fragment of human BPI possesses the anti-bacterial efficacy of the naturally-derived 55 kD human BPI holoprotein. [Ooi et al., *J. Bio. Chem.*, 262: 14891-14894 (1987)]. In contrast to the N-terminal portion, the C-terminal region of the isolated human BPI protein displays only slightly detectable anti-bacterial activity against gram-negative organisms. [Ooi et al., *J. Exp. Med.*, 174:649 (1991).] An N-terminal BPI fragment of approximately 23 kD, referred to as "rBPI₂₃," has been produced by recombinant means and also retains anti-bacterial activity against gram-negative organisms [Gazzano-Santoro et al., *Infect. Immun.* 60:4754-4761 (1992)]. In that publication, an expression vector was used as a source of DNA encoding a recombinant expression product (rBPI₂₃). The vector was constructed to encode the 31-residue signal sequence and the first 199 amino acids of the N-terminus of the mature human BPI, as set out in SEQ ID NOS: 205 and 206 taken from Gray et al., *supra*, except that valine at position 151 is specified by GTG rather than GTC and residue 185 is glutamic acid (specified by GAG) rather than lysine (specified by AAG). Recombinant holoprotein, also referred to as rBPI, has also been produced having the sequence set out in SEQ ID NOS: 205 and 206 taken from Gray et al., *supra*, with the exceptions noted for rBPI₂₃. An N-terminal fragment analog designated rBPI₂₁ or rBPI₂₁Δcys has been described in co-owned, copending U.S. Patent No. 5,420,019. This analog comprises the first 193 amino acids of BPI holoprotein as set out in.....

SEQ ID NOS: 205 and 206 but wherein the cysteine at residue number 132 is substituted with alanine, and with the exceptions noted for rBPI₂₃.

The bactericidal effect of BPI has been reported to be highly specific to gram-negative species, e.g., in Elsbach and Weiss, *Inflammation: Basic Principles and Clinical Correlates*, eds. Gallin et al., Chapter 30, Raven Press, Ltd. (1992). BPI is commonly thought to be non-toxic for other microorganisms, including yeast, and for higher eukaryotic cells. Elsbach and Weiss (1992), *supra*, reported that BPI exhibits anti-bacterial activity towards a broad range of gram-negative bacteria at concentrations as low as 10^{-8} to 10^{-9} M, but that 100- to 1,000-fold higher concentrations of BPI were non-toxic to all of the gram-positive bacterial species, yeasts, and higher eukaryotic cells tested at that time. It was also reported that BPI at a concentration of 10^{-6} M or 160 $\mu\text{g/ml}$ had no toxic effect, when tested at a pH of either 7.0 or 5.5, on the gram-positive organisms *Staphylococcus aureus* (four strains), *Staphylococcus epidermidis*, *Streptococcus faecalis*, *Bacillus subtilis*, *Micrococcus lysodeikticus*, and *Listeria monocytogenes*. BPI at 10^{-6} M reportedly had no toxic effect on the fungi *Candida albicans* and *Candida parapsilosis* at pH 7.0 or 5.5, and was non-toxic to higher eukaryotic cells such as human, rabbit and sheep red blood cells and several human tumor cell lines. See also Elsbach and Weiss, *Advances in Inflammation Research*, ed. G. Weissmann, Vol. 2, pages 95-113 Raven Press (1981). This reported target cell specificity was believed to be the result of the strong attraction of BPI for lipopolysaccharide (LPS), which is unique to the outer membrane (or envelope) of gram-negative organisms.

The precise mechanism by which BPI kills gram-negative bacteria is not yet completely elucidated, but it is believed that BPI must first bind to the surface of the bacteria through hydrophobic and electrostatic interactions between the cationic BPI protein and negatively charged sites on LPS. LPS has been referred to as "endotoxin" because of the potent inflammatory response that it stimulates, *i.e.*, the release of mediators by host

- 2 2 0 0 0 6 9

inflammatory cells which may ultimately result in irreversible endotoxic shock. BPI binds to lipid A, reported to be the most toxic and most biologically active component of LPS.

5 In susceptible gram-negative bacteria, BPI binding is thought to disrupt LPS structure, leading to activation of bacterial enzymes that degrade phospholipids and peptidoglycans, altering the permeability of the cell's outer membrane, and initiating events that ultimately lead to cell death. [Elsbach and Weiss (1992), *supra*]. BPI is thought to act in two stages. The first is a sublethal stage that is characterized by immediate growth arrest, 10 permeabilization of the outer membrane and selective activation of bacterial enzymes that hydrolyze phospholipids and peptidoglycans. Bacteria at this stage can be rescued by growth in serum albumin supplemented media [Mannion et al., *J. Clin. Invest.*, 85:853-860 (1990)]. The second stage, defined by growth inhibition that cannot be reversed by serum albumin, occurs 15 after prolonged exposure of the bacteria to BPI and is characterized by extensive physiologic and structural changes, including apparent damage to the inner cytoplasmic membrane.

Initial binding of BPI to LPS leads to organizational changes that probably result from binding to the anionic groups in the KDO region of 20 LPS, which normally stabilize the outer membrane through binding of Mg^{++} and Ca^{++} . Attachment of BPI to the outer membrane of gram-negative bacteria produces rapid permeabilization of the outer membrane to hydrophobic agents such as actinomycin D. Binding of BPI and subsequent gram-negative bacterial killing depends, at least in part, upon the LPS 25 polysaccharide chain length, with long O-chain bearing, "smooth" organisms being more resistant to BPI bactericidal effects than short O-chain bearing, "rough" organisms [Weiss et al., *J. Clin. Invest.* 65: 619-628 (1980)]. This first stage of BPI action, permeabilization of the gram-negative outer envelope, is reversible upon dissociation of the BPI, a process requiring the 30 presence of divalent cations and synthesis of new LPS [Weiss et al., *J.*

Immunol. 132: 3109-3115 (1984)]. Loss of gram-negative bacterial viability, however, is not reversed by processes which restore the envelope integrity, suggesting that the bactericidal action is mediated by additional lesions induced in the target organism and which may be situated at the cytoplasmic membrane [Mannion et al., *J. Clin. Invest.* 86: 631-641 (1990)]. Specific investigation of this possibility has shown that on a molar basis BPI is at least as inhibitory of cytoplasmic membrane vesicle function as polymyxin B [In't Veld et al., *Infection and Immunity* 56: 1203-1208 (1988)] but the exact mechanism as well as the relevance of such vesicles to studies of intact organisms has not yet been elucidated.

Three separate functional domains within the recombinant 23 kD N-terminal BPI sequence have been discovered [Little et al., *J. Biol. Chem.* 269: 1865 (1994)]. These functional domains of BPI designate a region of the amino acid sequence of BPI that contributes to the total biological activity of the protein and were essentially defined by the activities of proteolytic cleavage fragments, overlapping 15-mer peptides and other synthetic peptides. Domain I is defined as the amino acid sequence of BPI comprising from about amino acid 17 to about amino acid 45. Peptides based on this domain are moderately active in both the inhibition of LPS-induced LAL activity and in heparin binding assays, and do not exhibit significant bactericidal activity. Domain II is defined as the amino acid sequence of BPI comprising from about amino acid 65 to about amino acid 99. Peptides based on this domain exhibit high LPS and heparin binding capacity and are bactericidal. Domain III is defined as the amino acid sequence of BPI comprising from about amino acid 142 to about amino acid 169. Peptides based on this domain exhibit high LPS and heparin binding activity and are bactericidal. The biological activities of functional domain peptides may include LPS binding, LPS neutralization, heparin binding, heparin neutralization or bactericidal activity.

- 2 2 0 0 0 6 9

Fungi are eukaryotic cells that may reproduce sexually or asexually and may be biphasic, with one form in nature and a different form in the infected host. Fungal diseases are referred to as mycoses. Some mycoses are endemic, i.e. infection is acquired in the geographic area that is the natural habitat of that fungus. These endemic mycoses are usually self-limited and minimally symptomatic. Some mycoses are chiefly opportunistic, occurring in immunocompromised patients such as organ transplant patients, cancer patients undergoing chemotherapy, burn patients, AIDS patients, or patients with diabetic ketoacidosis.

Fungal infections are becoming a major health concern for a number of reasons, including the limited number of anti-fungal agents available, the increasing incidence of species resistant to older anti-fungal agents, and the growing population of immunocompromised patients at risk for opportunistic fungal infections. The incidence of systemic fungal infections increased 600% in teaching hospitals and 220% in non-teaching hospitals during the 1980's. The most common clinical isolate is *Candida albicans* (comprising about 19% of all isolates). In one study, nearly 40% of all deaths from hospital-acquired infections were due to fungi. [Sternberg, *Science*, 266:1632-1634 (1994).]

Anti-fungal agents include three main groups. The major group includes polyene derivatives, including amphotericin B and the structurally related compounds nystatin and pimaricin. These are broad-spectrum anti-fungals that bind to ergosterol, a component of fungal cell membranes, and thereby disrupt the membranes. Amphotericin B is usually effective for systemic mycoses, but its administration is limited by toxic effects that include fever and kidney damage, and other accompanying side effects such as anemia, low blood pressure, headache, nausea, vomiting and phlebitis. The unrelated anti-fungal agent flucytosine (5-fluorocytosine), an orally absorbed drug, is frequently used as an adjunct to amphotericin B treatment for some

forms of candidiasis and cryptococcal meningitis. Its adverse effects include bone marrow depression with leukopenia and thrombocytopenia.

The second major group of anti-fungal agents includes azole derivatives which impair synthesis of ergosterol and lead to accumulation of metabolites that disrupt the function of fungal membrane-bound enzyme systems (e.g., cytochrome P450) and inhibit fungal growth. Significant inhibition of mammalian P450 results in significant drug interactions. This group of agents includes ketoconazole, clotrimazole, miconazole, econazole, butoconazole, oxiconazole, sulconazole, terconazole, fluconazole and itraconazole. These agents may be administered to treat systemic mycoses. Ketoconazole, an orally administered imidazole, is used to treat nonmeningeal blastomycosis, histoplasmosis, coccidioidomycosis and paracoccidioidomycosis in non-immunocompromised patients, and is also useful for oral and esophageal candidiasis. Adverse effects include rare drug-induced hepatitis; ketoconazole is also contraindicated in pregnancy. Itraconazole appears to have fewer side effects than ketoconazole and is used for most of the same indications. Fluconazole also has fewer side effects than ketoconazole and is used for oral and esophageal candidiasis and cryptococcal meningitis. Miconazole is a parenteral imidazole with efficacy in coccidioidomycosis and several other mycoses, but has side effects including hyperlipidemia and hyponatremia.

The third major group of anti-fungal agents includes allylamines-thiocarbamates, which are generally used to treat skin infections. This group includes tolnaftate and naftifine.

Another anti-fungal agent is griseofulvin, a fungistatic agent which is administered orally for fungal infections of skin, hair or nails that do not respond to topical treatment.

Most endemic mycoses are acquired by the respiratory route and are minimally symptomatic; cough, fever, headache, and pleuritic pain may be seen. Occasionally, endemic mycoses may cause progressive

- 2 2 0 0 0 6 9

pulmonary disease or systemic infection. Histoplasmosis, caused by *Histoplasma*, is the most common endemic respiratory mycosis in the United States; over 40 million people have been infected. The disease is noncontagious and ordinarily self-limited, but chronic pulmonary infection and disseminated infection may occur. Pulmonary infection rarely requires treatment, but disseminated infection may be treated with amphotericin B. Coccidioidomycosis, caused by *Coccidioides*, is a noncontagious respiratory mycosis prevalent in the southwest United States. It also is usually self-limited but may lead to chronic pulmonary infection or disseminated infection. Amphotericin B or miconazole may be given for treatment. Blastomycosis, caused by *Blastomyces* is a noncontagious, subacute or chronic endemic mycosis most commonly seen in the southeast United States. Most pulmonary infections are probably self-limited. Patients with progressive lung disease or disseminated disease, and immunocompromised patients, may be treated systemically with amphotericin B. Paracoccidioidomycosis, caused by *Paracoccidioides*, is a noncontagious respiratory mycosis that is the most common systemic mycosis in South America. It may be acute and self-limited or may produce progressive pulmonary disease or extrapulmonary dissemination. Disseminated disease is generally fatal in the absence of therapy. Sulfonamides may be used but have a low success rate. Amphotericin B produces a higher response rate but relapses may still occur.

Cryptococcosis is a noncontagious, often opportunistic mycosis. It is characterized by respiratory involvement or hematogenous dissemination, often with meningitis. A major etiologic agent is *C. neoformans*. Most pulmonary infections are probably overlooked, but cryptococcal meningitis, which accounts for 90% of reported disease, is dramatic and seldom overlooked. Cryptococcosis is a particular problem in immunocompromised patients; cryptococcal meningitis occurs in 7 to 10% of AIDS patients. The principal symptom of meningitis is headache; associated findings include mental changes, ocular symptoms, hearing deficits, nausea, vomiting, and

seizures. Without treatment, 80% of patients die within two years. In meningitis, cryptococci can be observed in India ink preparations of cerebrospinal fluid sediment, and can be cultured from the cerebrospinal fluid. Treatment is generally with fluconazole or the combination of amphotericin B and flucytosine, although amphotericin B does not cross the blood brain barrier.

Aspergillosis is a term that encompasses a variety of disease processes caused by *Aspergillus* species. *Aspergillus* species are ubiquitous; their spores are constantly being inhaled. Of the more than 300 species known, only a few are ordinarily pathogenic for man: *A. fumigatus*, *A. flavus*, *A. niger*, *A. nidulans*, *A. terreus*, *A. sydowi*, *A. flavatus*, and *A. glaucus*. Aspergillosis is increasing in prevalence and is particularly a problem among patients with chronic respiratory disease or immunocompromised patients. Among immunocompromised patients, aspergillosis is second only to candidiasis as the most common opportunistic mycosis and accounts for about 15% of the systemic mycoses in this group. Opportunistic pulmonary aspergillosis is characterized by widespread bronchial erosion and ulceration, followed by invasion of the pulmonary vessels, with thrombosis, embolization and infarction. Clinically, infection manifests as a necrotizing patchy bronchopneumonia, sometimes with hemorrhagic pulmonary infarction. In about 40% of cases, there is hematogenous spread to other sites. Aspergillosis is also a rare but devastating complication of burn wounds; amputation is often required for cure. Invasive aspergillosis is commonly fatal, so aggressive diagnosis and treatment is required. Blood, urine and cerebrospinal fluid cultures are rarely positive, but fungi can be seen in smears and biopsies. Amphotericin B can be given for treatment.

Mucormycosis is an acute suppurative opportunistic mycosis that produces rhinocerebral, pulmonary or disseminated disease in immunocompromised patients, and local or disseminated disease in patients with burns or open wounds. Infection is caused by fungi in the class Zygomycetes, and

- 2 2 0 0 0 6 9

10

include *Basidiobolus*, *Conidiobolus*, *Rhizopus*, *Mucor*, *Absidia*, *Mortierella*, *Cunninghamella*, and *Saksenaea*. Rhinocerebral mucormycosis accounts for about half of all cases of mucormycosis. It is one of the most rapidly fatal fungal diseases, with death occurring within 2-10 days in untreated patients.

5 Early clinical signs include nasal stuffiness, bloody nasal discharge, facial swelling and facial pain. The infection then spreads to the eyes, cranial nerves and brain. Pulmonary mucormycosis is nearly as common as rhinocerebral disease and manifests with the same necrotizing and infarction as aspergillosis. Fungi are virtually never seen or cultured from blood,

10 sputum or cerebrospinal fluid. Disseminated mucormycosis may follow pulmonary or burn wound infection. Treatment is with amphotericin B.

Candidiasis is a general term for a variety of local and systemic processes caused by colonization or infection of the host by species of the yeast *Candida*. Candidiasis occurs worldwide; superficial infections of the

15 skin, mouth and other mucus membranes are universal. Invasive systemic disease has become a problem due to the use of high doses of antibiotics that destroy normal bacterial flora, immunosuppressive agents, and agents toxic to bone marrow, *e.g.*, during cancer therapy. Neutropenia is a major risk factor for *Candida* dissemination. Candidiasis is also seen among

20 immunocompromised individuals such as AIDS patients, organ transplant patients, patients receiving parenteral nutrition, and cancer patients undergoing radiation treatment and chemotherapy. It is the most common opportunistic mycosis in the world. The most common etiologic agent is *Candida albicans*. Other infectious species include *C. tropicalis*, *C. parapsilosis*, *C. stellatoidea*,

25 *C. krusei*, *C. parakrusei*, *C. lusitaniae*, *C. pseudotropicalis*, *C. guilliermondi* and *C. glabrata*. *Candida albicans* is normally found in the mouth, throat, gastrointestinal tract and vagina of humans. Non-*albicans* species frequently colonize skin. *Candida* species occur in two forms that are not temperature- or host-dependent. The usual colonizing forms are yeasts that may assume a

30 pseudomycelial configuration, especially during tissue invasion.

Pseudomyceliae result from the sequential budding of yeasts into branching chains of elongated organisms.

Candida albicans contains cell wall mannoproteins that appear to be responsible for attachment of the yeast cells to specific host tissues. It has been reported that the mannan portion, rather than the protein portion, of the mannoproteins is responsible for adherence of fungal cells to spleen and lymph node tissues in mice. [Kanbe et al., *Infection Immunity*, 61:2578-2584 (1993).]

C. albicans also binds avidly to extracellular matrix (ECM) proteins such as fibronectin, laminin, and types I and IV collagen, all of which contain heparin-binding domains. This suggests *C. albicans* may express a heparin-like surface molecule. Adherence of *C. albicans* to the ECM may be important in the pathogenesis of disseminated candidiasis. It has been demonstrated that heparin, heparan sulfate and dextran sulfate glycosaminoglycans (GAGs) inhibit adherence of *C. albicans* to ECM and ECM proteins, possibly by a mechanism involving binding of GAGs to ECM proteins, thus masking these selective ligands. [Klotz et al., *FEMS Microbiology Letters*, 78:205-208 (1992).]

Clinically, candidiasis manifests as superficial mucocutaneous infections, chronic mucocutaneous candidiasis, or systemic infection. Superficial mucocutaneous infections can occur in any area of skin or mucus membrane. Thrush, commonly seen in AIDS patients, is characterized by a patchy or continuous, creamy to gray pseudomembrane that covers the tongue, mouth, or other oropharyngeal surfaces and may be accompanied by ulceration and necrosis. Laryngeal involvement results in hoarseness. Esophagitis is often an extension of oropharyngeal disease and may manifest with symptoms of retrosternal pain and dysphagia. Intestinal candidiasis is commonly asymptomatic, but is a major source of hematogenous invasion in immunocompromised individuals. Intertrigo involves the axillae, groins, inframammary folds, and other warm, moist areas, and may manifest as red,

2 2 0 0 0 6 9

12

oozing or dry, scaly lesions. Infections may occur in other areas, including perianal and genital areas. Paronychia, infection of the nails, often follows chronic exposure of the hands or feet to moisture. Some patients with limited T-cell immunodeficiency develop chronic mucocutaneous candidiasis. These patients suffer from persistent superficial *Candida* infection of the skin, scalp, nails and mucus membranes.

Most cases of systemic candidiasis are caused by *Candida albicans* and *C. tropicalis*, and increasingly, *C. glabrata*. Clinical manifestations of *Candida* infection appear mainly in the eyes, kidneys and skin. In the eyes, there may be single or multiple raised, white, fluffy chorioretinal lesions. These lesions are a potential cause of blindness. Involvement of the kidneys includes diffuse abscesses, capillary necrosis and obstruction of the ureters. Infection may result in progressive renal insufficiency. Systemic *Candida* infection can also manifest as maculonodular skin lesions surrounded by a reddened area; these lesions have an appearance similar to acne but are a major clue to a potentially lethal disease. Other manifestations of systemic candidiasis may include osteomyelitis, arthritis, meningitis, and abscesses in the brain, heart, liver, spleen and thyroid. Involvement of the lungs is also common, but pulmonary lesions are usually too small to be seen on chest X-ray. Finally, *Candida* endocarditis can occur in patients receiving prolonged intravenous therapy or cardiac valve implants, or in intravenous drug abusers. Fungal lesions appear on the valves, and can embolize and occlude large blood vessels.

Superficial infections are diagnosed by microscopic examination of scrapings or swabs of infected lesions in the presence of 10% potassium hydroxide. *Candida* organisms can also be seen on gram stain. Endocarditis is diagnosed by blood cultures or demonstration of bulky valvular lesions on echocardiography. Systemic candidiasis may be difficult to diagnose because the presence of heavy colonization at the usual sites of infection indicates, but does not prove, that dissemination has occurred. The most reliable evidence

of systemic candidiasis is biopsy demonstration of tissue invasion or recovery of yeast from fluid in a closed body cavity, such as cerebral spinal fluid, pleural or peritoneal fluid. Similarly, positive blood or urine or sputum cultures may indicate invasive disease or simply localized disease around
5 indwelling devices, *e.g.*, catheters or intravenous lines.

Mucocutaneous infections may be treated with topical preparations of nystatin, amphotericin B, clotrimazole, miconazole, haloprogin or gentian violet. Oropharyngeal or esophageal candidiasis can be treated with systemic agents such as ketoconazole or fluconazole. Chronic
10 mucocutaneous candidiasis syndrome may respond to topical or systemic therapeutic agents such as amphotericin B or ketoconazole, but often relapses when medication is discontinued. Cystitis may be treated with amphotericin B bladder rinses, or a brief low-dose intravenous course of amphotericin B with or without oral flucytosine. Endocarditis is essentially incurable without
15 valve replacement, accompanied by a 6 to 10 week course of amphotericin B and flucytosine. Even with therapy, however, complete cure of endocarditis is not always possible.

The mortality rate from systemic candidiasis is about 50%. Systemic candidiasis may be treated with fluconazole, a fungistatic agent, or
20 amphotericin B, a fungicidal agent although systemic use of the latter is limited by its toxicity. Both drugs have substantial adverse reactions when used in combination with cyclosporine A, which itself can be nephrotoxic. The removal of precipitating factors such as intravenous lines or catheters is also important for controlling infection. Flucytosine therapy can be added to
25 the amphotericin B therapy for treatment of systemic candidiasis, especially in patients that are not immunocompromised. In immunocompromised patients, however, these infections are problematic and resist effective treatment. Mortality with systemic candidiasis can be over 90% in such patients. Furthermore, chronic mucocutaneous candidiasis and candidal

- 2 2 0 0 0 6 9

14

endocarditis often show evidence of disease after having been declared cured.

There continues to exist a need in the art for new anti-fungal methods and materials. In particular, effective anti-fungal therapy for systemic mycoses is limited. Products and methods responsive to this need would ideally involve substantially non-toxic compounds available in large quantities by means of synthetic or recombinant methods. Ideal compounds would have a rapid effect and a broad spectrum of fungicidal or fungistatic activity against a variety of different fungal species when administered or applied as the sole anti-fungal agent. Ideal compounds would also be useful in combinative therapies with other anti-fungal agents, particularly where these activities would reduce the amount of anti-fungal agent required for therapeutic effectiveness, enhance the effect of such agents, or limit potential toxic responses and high cost of treatment.

15

SUMMARY OF THE INVENTION

The present invention provides novel peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and therapeutic uses of such peptides as anti-fungal agents. Peptides of the invention are useful in methods of treating a subject suffering from a fungal infection by administering a therapeutically effective amount of the peptide. This is based on the surprising discovery that Domain III derived peptides have fungicidal/fungistatic effects. A second surprising discovery is that such peptides have LPS-neutralizing activity. This activity provides an additional benefit in the use of peptides of the invention for treating fungal infections. Domain III derived peptides may be administered alone or in conjunction with known anti-fungal agents. When made the subject of adjunctive therapy, the administration of Domain III derived peptides may reduce the amount of anti-fungal agent needed for effective therapy, thus limiting potential toxic response and/or high cost of treatment.

Administration of Domain III derived peptides may also enhance the effect of such agents, accelerate the effect of such agents, or reverse resistance of fungi to such agents.

5 In addition, the invention provides a method of killing or inhibiting growth of fungi comprising contacting the fungi with a Domain III derived peptide. This method can be practiced *in vivo* or in a variety of *in vitro* uses such as to decontaminate fluids and surfaces and to sterilize surgical and other medical equipment and implantable devices, including prosthetic joints and indwelling invasive devices.

10 A further aspect of the invention involves use of a Domain III derived peptide for the manufacture of a medicament for treatment of fungal infection. The medicament may include, in addition to a Domain III derived peptide, other chemotherapeutic agents such as anti-fungal agents.

15 Numerous additional aspects and advantages of the invention will become apparent to those skilled in the art upon considering the following detailed description of the invention, which describes the presently preferred embodiments thereof.

20 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 provides results of broth assay tests of the activity of various peptides against *C. albicans*.

25 Figures 2A and 2B provide results of radial diffusion assays of the activity of various peptides against *C. albicans* SLU-1 (Fig. 2A) and *C. albicans* SLU-2G (Fig. 2B).

Figure 3 provides results of broth assay tests of the activity of combinations of peptide and amphotericin B against *C. albicans*.

Figures 4, 5, and 6 graphically represent survival data in mice after *C. albicans* challenge and treatment with peptides or buffer control.

Figures 7 graphically represents survival data in cyclosporin-treated mice after *C. albicans* challenge and treatment with peptides or buffer control.

Figure 8 provides results of RAW cell assay tests of the activity of various peptides.

Figure 9 graphically represents survival data in mice after challenge with *E. coli* 0111:B4 LPS and treatment with peptide.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the surprising discovery that a Domain III derived peptide has fungicidal activity and can be administered to treat subjects suffering from fungal infection. Also provided are methods of treating fungal infections with such peptides. Unexpectedly, Domain III derived peptides were demonstrated to have anti-fungal activities both in *in vitro* killing assays and in *in vivo* models of fungal infection, as measured, for example, by improved survival or reduction of colony-forming units in circulation after fungal challenge. A variety of fungal infections, including infections caused by *Aspergillus*, infections caused by *Cryptococcus*, such as cryptococcal meningitis, and mucocutaneous and systemic candidiasis caused by *Candida* species, may be treated according to the invention. Also, unexpectedly, Domain III derived peptides were demonstrated to have LPS-neutralizing activity both in an *in vitro* assay and an *in vivo* model. This activity provides an additional benefit in the treatment of fungal infections where bacterial LPS from translocation or additional infection is associated with the fungal infection.

As used herein "Domain III derived peptide" includes peptides having an amino acid sequence of BPI protein from about position 142 to about position 169, subsequences thereof and variants of the sequence or subsequence thereof, which possess antifungal activity. Specifically included are those antifungal peptides having six to fourteen amino acids and having the

amino acid sequence of BPI protein from about position 148 to about position 161, subsequences thereof and variants of the sequence or subsequence. Certain preferred peptides have fourteen amino acids and among the preferred variant sequences and subsequences are those having K as an amino acid corresponding to G at position 152. Preferred peptide sequences with fourteen amino acids have a core amino acid sequence selected from the group consisting of LIQL, IQLF, WLIQL, LIQLF and WLIQLF or a variant core amino acid sequence having at least 75% homology to said core amino acid sequence and include the peptides of SEQ ID NOS: 4 (XMP.13), 6-19 (XMP.31-44), 21-22 (XMP.82-83), 23-25 (XMP.85-87), 26-27 (XMP.91-92), 28-31 (XMP.94-97), 32-33 (XMP.100-101), 34 (XMP.104), 35-40 (XMP.106-111), 41 (XMP.113), 42 (XMP.116), 43-55 (XMP.123-135), 57-58 (XMP.138-139), 59-61 (XMP.142-144), 62 (XMP.146), 66-78 (XMP.222-234), 80-88 (XMP.236-244), 89-109 (XMP.249-269) and 116 (XMP.283). This group of antifungal 14 mer peptides includes variant sequence peptides wherein at least one BPI sequence residue has been replaced by a D-isomer amino acid. See, *e.g.*, SEQ ID NOS: 46(XMP.126), 48 (XMP.128), 86-87 (XMP.242-243) and 92-93 (XMP.252-253). Variants involving BPI sequence replacements by atypical amino acids such as β (1-naphthyl)A, β (2-naphthyl)A, para-amino F, cyclohexyl A, α - and γ -aminobutyric acids, α methyl A and N-methyl G, V and L are also included within this group.

Among the presently preferred Domain III derived antifungal peptides of the invention having from seven to twelve amino acids comprising:

(a) a core sequence of amino acids selected from the group consisting of LIQL, IQLF, WLIQL, LIQLF and WLIQLF; and (b) one or more cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion of the core sequence. A subset of peptides have from seven to nine amino acids comprising: (a) a core sequence of amino acids selected from the group

consisting of LIQL and IQLF; and (b) at least two cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion of the core sequence. Another subset of peptides has from eight to ten amino acids comprising: (a)
5 a core sequence of amino acids selected from the group consisting of LIQLF and WLIQLF; and (b) at least two cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion of the core sequence. Still another subset of peptides has nine to twelve amino acids comprising: (a) a core sequence of
10 amino acids selected from the group consisting of WLIQLF; and (b) at least three cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion of the core sequence. Illustrating these subsets are the peptides of SEQ ID NOS: 118-137 (XMP.285-304), 140-144 (XMP.307-311), 155-160
15 (XMP.322-327), 166-170 (XMP.335-339), 174-177 (XMP.343-346), 179-184 (XMP.348-353), 186 (XMP.355), 188-190 (XMP.357-359).

It will be apparent from consideration of the structures of the above-described peptides that the Domain III sequence of BPI amino acids from 148 to 161 includes the core sequence(s) noted above as well as multiple
20 cationic residues (K and H) flanking the core. This motif is carried forward in the structures of subsequences of the 148 to 161 sequence providing antifungal peptides of the invention and also preserved in antifungal variants of the 148 to 161 sequence and subsequences thereof. Note, for example that when the G residue normally in the BPI sequence at position 152 is replaced
25 by K, this replacement serves to provide a cationic residue immediately adjacent to the predominantly hydrophobic core residues. Sequence and subsequence variants providing antifungal peptides according to the invention thus include those peptides wherein one or more existing non-cationic residues ordinarily flanking the core sequence(s) are replaced by cationic residues.

Within the core sequence(s), the neutral aliphatic residues L and I are each replaceable by neutral aliphatic residues G, A, V, I and L. Likewise, the aromatic residues W (BPI position 153) and F (BPI position 158) are replaceable by a different aromatic amino acid residues or by neutral aliphatic residues G, A, V, I and L. Moreover, the core sequence Q (BPI residue 156) is replaceable preferably by a neutral hydrophilic amino acid T, S and N. As noted above, where variations are introduced into core subsequence(s), it is preferable that the variant core sequence(s) retain 75% homology to the sequences occurring in BPI.

Antifungal Domain III peptides of the invention have one or more D-isomer amino acids, as illustrated by the peptides of SEQ ID NOS: 164 (XMP.333), 165 (XMP.334), 173 (XMP.342), 194 (XMP.363) and 196 (XMP.365) and have the core sequence amino acids comprise D-isomer amino acids in reverse sequence order as illustrated by peptides having the amino acid sequence set out in SEQ ID NOS: 163 (XMP.332) and 198 (XMP.367). The antifungal peptides can have an acetylated amino terminal amino acid residue as illustrated by the peptides of SEQ ID NOS: 162 (XMP.331), 185 (XMP.354), 187 (XMP.356), 195 (XMP.364), 199 (XMP.368) and 204 (XMP.373). Cyclic antifungal peptides as illustrated by SEQ ID NOS: 191-193 (XMP.360-362) are also within the scope of the invention.

Additional Domain III antifungal peptides of the invention include antifungal peptides SEQ ID NOS: 1 (XMP.5), 2-4 (XMP.11-13), 5 (XMP.29), 20 (XMP.55), 56 (XMP.137), 79 (XMP.235), 111-115 (XMP.271-275), 117 (XMP.284), 132 (XMP.299), 138-139 (XMP.305-306), 145-154 (XMP.312-321), 200-203 (XMP.369-372), 171-172 (XMP.340-341) and BPI residues 145-159 and 149-163 of SEQ ID NO:206.

Pharmaceutical compositions of the invention comprise a Domain III derived peptide and a pharmaceutically acceptable diluent, adjuvant or carrier and are administered topically, intravenously, orally or as an aerosol.

In vitro methods of the invention permit killing or inhibiting replication of fungi through contacting the fungi with an antifungal peptide or pharmaceutical composition containing the same. Fungal infection treatment methods of the invention comprise administering to a subject suffering from a fungal infection a therapeutically effective amount of a Domain III antifungal peptide and such treatment methods are applicable to infections by fungal infection involves a fungal species selected from the group consisting of *Candida* (especially, *C. albicans*, *C. glabrata*, *C. krusei*, *C. lusitaniae*, *C. parapsilosis* and *C. tropicalis*), *Aspergillus* and *Cryptococcus* species.

As described in detail medicaments/pharmaceutical compositions developed according to the invention can include other antifungal agents including non-peptide agents or can be used in combinative therapeutic methods with other such agents.

Peptides derived from or based on BPI produced by recombinant or synthetic means (BPI-derived peptides) have been described in co-owned and copending PCT Application No. WO95/19372 filed September 15, 1994, which corresponds to U.S. Patent No. 5,652,332, U.S. Patent No. 5,733,872 and U.S. Patent No. 5,348,942 (disclosing, *inter alia*, overlapping 15-mer peptides having BPI residues 145-159 and 149-163 of SEQ ID NO. 206). BPI-derived peptides having an amino acid sequence of BPI protein from about position 142 to about position 169, subsequences thereof and variants of the sequence or subsequence thereof, which possess a BPI antifungal biological activity, were disclosed in co-owned U.S. Patent No. 5,627,153.

The Domain III derived peptide may be administered systemically or topically. Systemic routes of administration include oral, intravenous, intramuscular or subcutaneous injection (including into depots for long-term release), intraocular or retrobulbar, intrathecal, intraperitoneal (e.g. by intraperitoneal lavage), transpulmonary using aerosolized or nebulized drug, or transdermal. Topical

routes include administration in the form of salves, ophthalmic drops, ear drops, or irrigation fluids (for, e.g. irrigation of wounds).

5 The Domain III derived peptide may be administered in conjunction with other anti-fungal agents. Preferred anti-fungal agents for this purpose are amphotericin B and fluconazole. Concurrent administration of Domain III derived peptide with anti-fungal agents is expected to improve the therapeutic effectiveness of the anti-fungal agents. This
10 may occur through reducing the concentration of anti-fungal agent required to eradicate or inhibit fungal growth, e.g., replication. Because the use of some agents is limited by their systemic toxicity or prohibitive cost, lowering the concentration of anti-fungal agent required for therapeutic effectiveness reduces toxicity and/or cost of treatment, and
15 thus allows wider use of the agent. Concurrent administration of Domain III derived peptide and another anti-fungal agent may produce a more rapid or complete fungicidal/fungistatic effect than could be achieved with either agent alone. Domain III derived peptide
20 administration may reverse the resistance of fungi to anti-fungal agents. Domain III derived peptide administration may also convert a fungistatic agent into a fungicidal agent.

25 An advantage provided by the present invention is the ability to treat fungal infections, particularly *Candida* infections, that are presently considered incurable. Another advantage is the ability to treat fungi that have

acquired resistance to known anti-fungal agents. A further advantage of concurrent administration of Domain III derived peptide with an anti-fungal agent having undesirable side effects, *e.g.*, amphotericin B, is the ability to reduce the amount of anti-fungal agent needed for effective therapy. The present invention may also provide quality of life benefits due to, *e.g.*, decreased duration of therapy, reduced stay in intensive care units or reduced stay overall in the hospital, with the concomitant reduced risk of serious nosocomial (hospital-acquired) infections.

"Concurrent administration" as used herein includes administration of the agents together, simultaneously or before or after each other. The Domain III derived peptide and anti-fungal agents may be administered by different routes. For example, the Domain III derived peptide may be administered intravenously while the anti-fungal agents are administered intramuscularly, intravenously, subcutaneously, orally or intraperitoneally. Alternatively, the Domain III derived peptide may be administered intraperitoneally while the anti-fungal agents are administered intraperitoneally or intravenously, or the Domain III derived peptide may be administered in an aerosolized or nebulized form while the anti-fungal agents are administered, *e.g.*, intravenously. The Domain III derived peptide and anti-fungal agents may be both administered intravenously. The Domain III derived peptide and anti-fungal agents may be given sequentially in the same intravenous line, after an intermediate flush, or may be given in different intravenous lines. The Domain III derived peptide and anti-fungal agents may be administered simultaneously or sequentially, as long as they are given in a manner sufficient to allow both agents to achieve effective concentrations at the site of infection.

Concurrent administration of Domain III derived peptide and another anti-fungal agent is expected to provide more effective treatment of fungal infections. Concurrent administration of the two agents may provide greater therapeutic effects *in vivo* than either agent provides when

administered singly. For example, concurrent administration may permit a reduction in the dosage of one or both agents with achievement of a similar therapeutic effect. Alternatively, the concurrent administration may produce a more rapid or complete fungicidal/fungistatic effect than could be achieved with either agent alone.

Therapeutic effectiveness is based on a successful clinical outcome, and does not require that the anti-fungal agent or agents kill 100% of the organisms involved in the infection. Success depends on achieving a level of anti-fungal activity at the site of infection that is sufficient to inhibit the fungi in a manner that tips the balance in favor of the host. When host defenses are maximally effective, the anti-fungal effect required may be minimal. Reducing organism load by even one log (a factor of 10) may permit the host's own defenses to control the infection. In addition, augmenting an early fungicidal/fungistatic effect can be more important than long-term fungicidal/fungistatic effect. These early events are a significant and critical part of therapeutic success, because they allow time for host defense mechanisms to activate.

A Domain III derived peptide may interact with a variety of host defense elements present in whole blood or serum, including complement, p15 and LBP, and other cells and components of the immune system. Such interactions may result in potentiation of the activities of the peptide. Because of these interactions, Domain III derived peptides can be expected to exert even greater activity *in vivo* than *in vitro*. Thus, while *in vitro* tests are predictive of *in vivo* utility, absence of activity *in vitro* does not necessarily indicate absence of activity *in vivo*. For example, BPI has been observed to display a greater bactericidal effect on gram-negative bacteria in whole blood or plasma assays than in assays using conventional media. [Weiss et al., *J. Clin. Invest.* 90:1122-1130 (1992)]. This may be because conventional *in vitro* systems lack the blood elements that facilitate or potentiate BPI's function *in vivo*, or because conventional media contain

higher than physiological concentrations of magnesium and calcium, which are typically inhibitors of the activity of BPI protein products. Furthermore, in the host, Domain III derived peptides are available to neutralize translocation of gram-negative bacteria and concomitant release of endotoxin, a further clinical benefit not seen in or predicted by *in vitro* tests of anti-fungal activity.

It is also contemplated that the Domain III derived peptides be administered with other products that potentiate the activity of the peptide, including the anti-fungal activity of the peptides. For example, serum complement potentiates the gram-negative bactericidal activity of BPI protein products; the combination of BPI protein product and serum complement provides synergistic bactericidal/growth inhibitory effects. See, e.g., Ooi et al. J. Biol. Chem., 265: 15956 (1990) and Levy et al. J. Biol. Chem., 268: 6038-6083 (1993) which address naturally-occurring 15 kD proteins potentiating BPI antibacterial activity. See also co-owned, co-pending PCT Application No. W095/02414 filed July 13, 1994, which corresponds to U.S. Patent No. 5,770,561. These describe methods for potentiating gram-negative bactericidal activity of BPI protein products by administering lipopolysaccharide binding protein (LBP) and LBP protein products. LBP protein derivatives and derivative hybrids which lack CD-14 immunostimulatory properties are described in PCT Application No. W095/00641 filed June 17, 1994, which corresponds to co-owned U.S. Patent No. 5,731,415. It has also been observed that poloxamer surfactants enhance the anti-bacterial activity of BPI protein products

poloxamer surfactants may also enhance the activity of anti-fungal agents.

Without being bound by a theory of the invention, it is believed that Domain III derived peptides may have several modes of action. The peptide, through its heparin-binding ability, may interfere with the binding of fungi to the extracellular matrix. For example, heparin-like surface molecules of *Candida* are believed to mediate adhesion of the yeast to extracellular matrix and host tissues. The peptide may also act directly on the cytoplasmic membrane of fungi. In addition, the peptide may bind to fungal cell wall mannoproteins that are structurally similar to the LPS of gram-negative organisms or that are responsible for adherence to target host tissues, thus interfering with fungal interaction with host tissues. Binding to fungal mannans may also promote access of the peptide to the inner cytoplasmic membrane. In addition, because fungal infection may cause stress-induced translocation of bowel flora and/or LPS, the peptide may also act beneficially by killing gram-negative bacteria and neutralizing LPS. Finally, the antifungal activity of Domain III peptides according to the invention may result from unique structural features. For example, a six amino acid sequence within Domain III (WLIQLF) and the included five and four amino acid sequences (LIQL, IQLF, WLIQL and LIQLF) are composed of hydrophobic amino acids with the exception of glutamine (Q) that is a neutral hydrophilic amino acid. This hydrophobic stretch is bounded by highly cationic (polar) lysines on the N- and C-termini. This motif is reminiscent of leader/signal peptides as well as transmembrane segments of membrane proteins. Aliphatic amino acids such as I, L, V, M, A, have a high propensity to form transmembrane α -helical structures within the hydrophobic membrane environment when found in sequences of 12-15 nonpolar amino acids due to their ability to form backbone hydrogen bonds. Aromatic hydrophobic amino acids such as W and F can also incorporate into a membrane α -helix. The neutral, hydrophilic glutamine in the middle of a

Domain III hydrophobic stretch may participate in hydrogen bonding with other fungal membrane components such as ergosterol and thus play an important role in the fungicidal activity. A short 10 amino acid peptide (*e.g.*, XMP.293) is not expected to be long enough to span a lipid bilayer and probably has a much different mechanism of action than a membrane disrupting, amphipathic type of cationic antimicrobial peptide. The short motif of six to twelve amino acid peptides with a core of neutral amino acids bounded by cationic amino acids is not long enough to span a fungal lipid bilayer and thus may be allowed to traverse the membrane bilayer more efficiently than longer peptides. If transported inside the cell, the cationic/neutral/cationic molecules may inhibit the function of endogenous polyamines (spermidine, spermine, putrescine) by either competitive inhibition of the polyamine regulation of cell wall carbohydrate synthesis and/or by feedback inhibition of polyamine synthesis.

In addition, the invention provides a method of killing or inhibiting growth of fungi comprising contacting the fungi with a Domain III derived peptide. This method can be practiced *in vivo* or in a variety of *in vitro* uses such as use in food preparations or to decontaminate fluids and surfaces or to sterilize surgical and other medical equipment and implantable devices, including prosthetic joints. These methods can also be used for *in situ* sterilization of indwelling invasive devices such as intravenous lines and catheters, which are often foci of infection.

A further aspect of the invention involves use of a Domain III derived peptide for the manufacture of a medicament for treatment of fungal infection. The medicament may include, in addition to a BPI protein product, other chemotherapeutic agents such as anti-fungal agents. The medicament can optionally comprise a pharmaceutically acceptable diluent, adjuvant or carrier.

The administration of antifungal peptides is suitably accomplished with a pharmaceutical composition comprising a peptide and a

pharmaceutically acceptable diluent, adjuvant, or carrier. The peptide may be administered without or in conjunction with known surfactants, other chemotherapeutic agents or additional known anti-fungal agents.

Other aspects and advantages of the present invention will be understood upon consideration of the following illustrative examples wherein Example 1 addresses peptide preparation and purification; Example 2 addresses *in vitro* anti-fungal testing of peptides; Example 3 addresses additional *in vitro* and *in vivo* testing of the anti-fungal effect of peptides on a variety of fungal species, including *Candida* strains and antibiotic resistant strains; Example 4 addresses the *in vivo* effect of peptides on survival of mice challenged with *Candida*; Example 5 addresses the serum stability of peptides; Example 6 addresses the design and assay of anti-fungal peptides for structural motif and minimum functional sequence analysis; Example 7 addresses LPS neutralization activities of anti-fungal peptides; and Example 8 addresses peptide formulations.

20

25

30

Example 1

PEPTIDE PREPARATION AND PURIFICATION

This example addresses the preparation and purification of Domain III derived peptides.

5 Peptides may be prepared according to a variety of synthetic procedures. Some peptides (e.g., XMP.5) were prepared by solid phase peptide synthesis as described in parent U.S. Patent No. 5,733,872 according to the methods of Merrifield, *J. Am Chem. Soc.* 85: 2149 (1963) and Merrifield
10 *et al. Anal. Chem.*, 38: 1905-1914 (1966) using an Applied Biosystems, Inc. Model 432 peptide synthesizer.

 Alternatively, peptides were synthesized on a larger scale using solid phase peptide synthesis on an Advanced Chemtech[®] (ACT-Model 357 MPS) synthesizer utilizing a 1-
15 Fluorenylmethyl-oxycarbonyl (Fmoc) protection strategy with a double coupling procedure employing N,N-diisopropylcarbodiimide (DIC)/1-hydroxybenzotriazole (HOBt) and 2-(1-H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium hexa-fluorophosphate (HBTU)/HOBt/diisopropylethylamine
20 (DIEA). The solid support used was a polystyrene resin with 1% divinylbenzene (DVB) cross-linking and an 4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxy (Fmoc-Rink amide) linker with a substitution rate of 0.44 mmoles/gram. The scale used was between 0.1 grams and 5 grams of starting
25 resin.

 Dimethylformamide (DMF) was the primary solvent with a 50/50 solution of piperidine/DMF used for Fmoc deprotection in three consecutive treatments of 1, 5, and 10 minutes, respectively. A double coupling procedure was used in each
30 cycle with a 4:1 amino acid to peptide ratio used in each coupling. The amino acids were dissolved in a 0.5M HOBt solution in N-methylpyrrolidinone (NMP) at a concentration also of 0.5M. For the first coupling, an equimolar (to amino acid) amount of a 0.5M solution of
35 diisopropylcarbodiimide (DIPCDI) in NMP was used and allowed

to react for 45 minutes. The second coupling utilized an equimolar (to amino acid) volume of a 0.5M HBTU solution in DMF with an equal volume of a 1M DIEA solution in NMP (2:1, DIEA:amino acid) for a period of 30 minutes.

5 Upon completion of the synthesis, the resin was treated with MeOH, dried under vacuum, and then cleaved using a cocktail composed of trifluoroacetic acid (TFA): thioanisole: ethanedithiol (EDT): water, at a ratio of 36:2:1:1 (volume was dependent on the amount of resin) for a minimum of 2
10 hours with an additional 30 minutes added for each arginine (but not exceeding 3 hours) with the first 15 minutes occurring in a wet ice bath. The solutions were then dissolved in a 10% TFA in water solution, washed 3 times with methyl t-butyl ether (MTBE) and lyophilized.

15 The amino termini of selected peptides were acetylated after synthesis on solid phase using an N-terminal Fmoc protection strategy as described above. Subsequent to Fmoc removal with piperidine and prior to peptide cleavage with TFA, the peptide on the resin was derivatized with a 10-fold
20 molar excess of acetic anhydride with a 2-fold molar excess of diisopropylethylamine in dimethylformamide for one hour. The peptide was then cleaved from the resin with the TFA cleavage cocktail as described above and purified as described below. N-terminal acetylation of the purified
25 peptide was verified by mass spectrometry.

For purity analysis of each newly synthesized peptide, dilute solutions of crude lyophilized peptides were prepared and analyzed on a Michrom® Ultrafast Microprotein Analyzer equipped with a 150 mm X 1 mm, 5 μ particle, 300 Å pore C-8
30 Zorbax® column. The column oven was set to 40°C., the flow rate was 100 μ L/minute, and injection volumes were typically 5-10 μ L. HPLC was performed using 5% acetonitrile/0.1% TFA in water as mobile phase A, and 80% acetonitrile/0.065 % TFA as mobile phase B. The eluate was monitored
35 spectrophotometrically at 214 nm. Percent purity is calculated from the peak area of the individual peptides (see Table 1).

Selected peptides were purified by high performance liquid chromatography (HPLC), using a Waters® Prep LC 2000 Preparative Chromatography System (Water Corp., Milford, MA) equipped with a Delta Pak® C-18, 15 μ m, 300 Å cartridge column consisting of a 40 X 10 mm guard cartridge and a 40 X 100 mm Prep Pak® cartridge. The column was equilibrated in 25% buffer B, where A=5% acetonitrile/0.1% trifluoroacetic acid and B=80% acetonitrile/0.065% trifluoroacetic acid. Peptides were dissolved to ~20 mg/mL in buffer A and 200-800 mg were applied to the column through the LC pump operating at a flow rate of 8-17 mL/min. Bound material was eluted with a gradient of 25-35 % buffer B/30 min applied at 8-17 mL/min. (Some peptides were purified with a gradient of 23-33%B/30 min.) The eluate was monitored at 220 and/or 280 and 300 nm with a Waters 490E Programmable Multiwavelength Detector. Fractions were collected and assayed for the peptide of interest on an Ultrafast Micoprotein Analyzer (Michrom BioResources, Inc., Pleasanton, CA) equipped with a Zorbax C-8, 150 X 1 mm, 5 μ m, 300 Å maintained at 40°C. Fractions containing the peptide of interest at $\geq$ 95% purity were pooled and lyophilized to dryness. The purity of the recovered material was determined with analytical reverse-phase HPLC.

Example 2

IN VITRO ANTI-FUNGAL EFFECTS

This example addresses in vitro screening of Domain III derived peptides for anti-fungal activity in a broth assay and/or in a radial diffusion assay.

Table 1 below sets out peptides derived from or based on Domain III BPI sequences. Such peptides may be identified by peptide number with a prefix XMP or BPI (e.g., XMP.1 or BPI.1, XMP.2 or BPI.2, etc.). Table 1 also sets out the SEQ ID NO: of each peptide, the amino acid sequence based on reference to position within BPI and the designation of amino acid

substitutions and additions. Also set out in Table 1 are HPLC estimates of purity of the peptides. The HPLC purity analysis was performed as described in Example 1.

5 In each broth assay screening procedure, a colony of *C. albicans* designated CA-1, Strain SLU-1 that was received from the laboratories of G. Matuschak and A. Lechner, St. Louis University Hospital, St. Louis, MO, where the strain was maintained, was inoculated into a tube containing 5 mL Sabouraud Dextrose broth (2% dextrose, 1% neopeptone) and incubated overnight at 37°C with shaking. The overnight culture was
10 diluted 1:50 into 5 mL of fresh broth and incubated for 3 hours at 37°C. Organisms were pelleted by centrifugation in a Beckman J-6M centrifuge for 5 minutes at 3000 rpm (1500 x g) and the pellets were resuspended in 5 mL phosphate buffered saline (PBS) and the optical density at 570 nm was determined. On the basis of the determination that one OD unit equals 3 x
15 10^7 colony forming units/mL, yeast cells were diluted to 2×10^6 cells/mL in Sabouraud Dextrose broth.

Domain III peptides derived from or based on BPI to be screened were originally constituted in Dulbecco's-PBS, were diluted to 100 μ g/mL in broth and were serially diluted 2-fold into wells of a 96 well sterile,
20 flat bottom, non-pyrogenic tissue culture plate (Costar, Cambridge, MA). All assays were performed in triplicate. 2×10^5 organisms were added at 100 μ l per well; final volume was 200 μ L/well; the plate was incubated on a shaker at 37°C for 18 hours; and the optical densities for each well were read at 590 nm. Figure 1 hereto graphically illustrates the dose response curves for five
25 peptides (XMP.13, XMP.138, XMP.139, XMP.142 and XMP.143). All illustrated peptides reduced optical density of the cultures to below 0.1 at doses of less than about 50 μ g/mL, with XMP.138 displaying the best results of the illustrated peptides at low dosages. The broth assay data may be set out in terms of minimum inhibitory concentration (MIC), *i.e.* the lowest
30 concentration required to reduce the optical density at 590 nm to below 0.1.

The MIC ($\mu\text{g/mL}$) of each of the five peptides listed above in FIG. 1 is 12.5, 3.13, 6.25, 12.5 and 25.0, respectively.

5 In the radial diffusion assay procedures, the CA-1 cultures and peptide solutions were prepared as in the broth assay procedure described above. Ten mL of molten underlayer agarose comprising 3% Sabouraud Dextrose broth, 1% agarose (Pharmacia, Piscataway, N.J.), 0.02% Tween[®] 20, and 10 mM sodium phosphate at pH 7.4, was added to polystyrene tubes and maintained in a 56°C. water bath until the addition of yeast. Tubes were cooled to approximately 45°C., yeast were added to give a final concentration of 1×10^6 CFU/mL, and the tubes were mixed again by inverting. The contents were poured into level square petri dishes and distributed evenly. The agarose solidified in less than 30 seconds and had a uniform thickness of about 1 mm. A series of wells were punched into the hardened agarose using a sterile 3 mm punch attached to a vacuum apparatus.

20 Peptides to be assayed were 2-fold serially diluted in Dulbecco's PBS (D-PBS) starting from a concentration of approximately 1 mg/mL. Five μL of each dilution were added to each well and the plates were incubated at 37°C. for 3 hours. An overlayer of 10 mL of molten agarose comprising 6% Sabouraud Dextrose broth, 1% agarose, and 10 mM sodium phosphate, pH 7.4, (at approximately 45°C) was then added and plates were incubated overnight at 37°C. Following this overnight incubation, a dilute Coomassie solution was poured into the plates and allowed to stain for 24 hours.

30 Clear zones of growth inhibition around each well were measured with calipers. The actual area of growth inhibition (mm^2) was calculated by subtracting the area of the well. Table 1 below sets out the results of the radial diffusion assays for tested peptides in terms of the number of picomoles (pmol) of peptide required to establish a 30 mm^2 area of growth inhibition calculated by PROBIT[®] analysis (e.g., calculated from regression of the linear portion of log-concentration dose-response curve, log pmol/well vs. net area of inhibition).

- 2 2 0 0 0 6 9
- 33 -

TABLE 1

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.5 (1)	142-163	18	>2151
XMP.11 (2)	148-151,153-161	76	645
XMP.12 (3)	141-169	26	>2099
XMP.13 (4)	148-161	69	541
XMP.13P ^f (4)	148-161	98	222
XMP.29 (5)	(148-161) x 2	26	>1469
XMP.31 (6)	148-161, A @ 148 (K)	68	426
XMP.32 (7)	148-161, A @ 149 (S)	70	294
XMP.33 (8)	148-161, A @ 150 (K)	58	603
XMP.34 (9)	148-161, A @ 151 (V)	51	319
XMP.35 (10)	148-161, A @ 152 (G)	72	442
XMP.36 (11)	148-161, A @ 153 (W)	64	197

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.36 (11)	148-161, A @ 153 (W)	99	231
XMP.37 (12)	148-161, A @ 154 (L)	51	253
XMP.38 (13)	148-161, A @ 155 (I)	70	391
XMP.39 (14)	148-161, A @ 156 (Q)	53	1792
XMP.40 (15)	148-161, A @ 157 (L)	53	253
XMP.41 (16)	148-161, A @ 158 (F)	63	734
XMP.42 (17)	148-161, A @ 159 (H)	59	548
XMP.43 (18)	148-161, A @ 160 (K)	53	785
XMP.44 (19)	148-161, A @ 161 (K)	70	578
XMP.55 (20)	152-172	28	>2666
XMP.82 (21)	148-161, W @ 158 (F)	58	518

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.83 (22)	148-161, β (1-naphthyl)-A @ 153 (W)	63	1804
XMP.85 (23)	148-161, L @ 152 (G)	74	>1881
XMP.86 (24)	148-161, L @ 156 (Q)	51	>2048
XMP.87 (25)	148-161, L @ 159 (H)	63	>1536
XMP.91 (26)	148-161, F @ 156 (Q)	31	>3844
XMP.92 (27)	148-161, K @ 156 (Q)	50	299
XMP.94 (28)	148-161, F @ 159 (H)	59	>923
XMP.95 (29)	148-161, F @ 152 (G)	57	>1398
XMP.96 (30)	148-161, F @ 161 (K)	60	1856
XMP.97 (31)	148-161, K @ 152 (G)	67	213

1 2 2 0 0 0 6 9

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.97P ^f (31)	148-161, K @ 152 (G)	98	303.5
XMP.100 (32)	148-161, K @ 152 (G) & 156 (Q)	61	462
XMP.101 (33)	(148-161) x 2[K @ 152(G) & 156(Q), F @ 159(H) & 161(K)]	16	> 1040
XMP.104 (34)	148 - 161, S @ 156 (Q)	34	> 5569
XMP.106 (35)	148 - 161, T @ 156 (Q)	26	1032
XMP.107 (36)	148 - 161, W @ 159 (H)	55	> 2796
XMP.108 (37)	148 - 161, W @ 161 (K)	50	> 3219
XMP.109 (38)	148-161, β (1-naphthyl)-A @ 158 (F)	41	> 2839
XMP.110 (39)	148-161, β (1-naphthyl)-A @ 159 (H)	56	> 2922

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.111 (40)	148-161, β (1-naphthyl)-A @ 161 (K)	73	> 2809
XMP.113 (41)	148 - 161, F @ 157 (L)	46	947
XMP.116 (42)	148-161, K @ 152 (G), β (1-naphthyl)-A @ 153 (W)	72	670
XMP.123 (43)	148-161, p-Amino-F @ 156 (Q)	64	1721
XMP.124 (44)	148-161, K @ 152(G), W @ 158 (F)	67	351
XMP.125 (45)	148-161, Y @ 156 (Q)	54	> 3150
XMP.126 (46)	148-161, W _D @ 153 (W)	54	1404
XMP.127 (47)	148-161, F @ 153 (W)	63	226
XMP.127P ^f (47)	148-161, F @ 153 (W)	94	935
XMP.128 (48)	148-161 F _D @ 153 (W)	51	1179

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.129 (49)	148-161, β (1-naphthyl)A _D @ 153 (W)	28	2117
XMP.130 (50)	148-161, β (2-naphthyl)A @ 153 (W)	80	1159
XMP.131 (51)	148-161, β (2-naphthyl)A _D @ 153 (W)	60	2493
XMP.132 (52)	148 - 161, PYR @ 153 (W)	50	353
XMP.133 (53)	148-161, p-Amino-F @ 153 (W)	47	284
XMP.134 (54)	148-161, p-Amino-F @ 152 (G)	68	1255
XMP.135 (55)	148-161, K @ 153 (W)	70	428
XMP.137 (56)	C-148-161-C	28	>2286
XMP.138 (57)	148-161, K @ 152 (G), F @ 153 (W)	61	257
XMP.139 (58)	148-161, Y @ 153 (W)	60	323

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.142 (59)	148-161, W @ 157 (L)	57	1244
XMP.143 (60)	148-161, β (1-naphthyl)-A @ 157 (L)	65	>2839
XMP.144 (61)	148-161, Cyclohexyl-A @ 153 (W)	60	695
XMP.146 (62)	148-161, β (1-naphthyl)-A @ 159 (H) & 161 (K)	53	b
XMP.148 (63)	148-161, β (1-naphthyl)-A @ 153 (W) & 159 (H)	62	>2805
XMP.161 (64)	148-161, K @ 152 (G) & A @ 153 (W)	75	>2999
XMP.166 (65)	148-161, V @ 153 (W)	68	171
XMP.222 (66)	148-161 β (1-naphthyl)-A @ 153 (W) & 161 (K)	57	>2,610

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.223 (67)	148-161, β (1-naphthyl)-A @ 153 (W) & 157 (L)	39	b
XMP.224 (68)	148-161, β (1-naphthyl)-A @ 153, p-amino- F @ 156 (Q)	55	>2,443
XMP.225 (69)	148-161, p-amino-F @ 152, β (1-naphthyl)- A @ 153 (W)	77	>2,506
XMP.226 (70)	148-161, β (1-naphthyl)-A @ 153, W @ 158 (F)	50	>2,597
XMP.227 (71)	148-161, β (1-naphthyl)-A @ 157 (L) & 161 (K)	54	>2,365
XMP.228 (72)	148-161, p-amino-F @ 156 (Q), β (1- naphthyl)-A @ 161 (K)	43	b
XMP.229 (73)	148-161, p-amino-F @ 152 (G), β (1- naphthyl)-A @ 161 (K)	81	b

TABLE 1 (continued)

	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.230 (74)	148-161, W @ 158 (F), β (1-naphthyl)-A @ 161 (K)	51	>2,386
XMP.231 (75)	148-161, β (1-naphthyl)-A @ 157 (L) & 159 (H)	44	b
XMP.232 (76)	148-161, p-amino-F @ 156 (Q), β (1- naphthyl)-A @ 159 (H)	28	b
XMP.233 (77)	148-161, p-amino-F @ 152 (G), β (1- naphthyl)-A @ 159 (H)	53	b
XMP.234 (78)	148-161, W @ 158 (F), β (1-naphthyl)-A @ 159 (H)	26	b
XMP.235 (79)	148-161, p-amino-F @ 156 (Q), β (1- naphthyl)-A @ 157 (L)	30	b
XMP.236 (80)	148-161, p-amino-F @ 152 (G), β (1- naphthyl)-A @ 157 (L)	73	>2,631

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.237 (81)	148-161, β (1-naphthyl)-A @ 157 (L), W @ 158 (F)	34	>2,777
XMP.238 (82)	148-161, p-amino-F @ 152 (G) & 156 (Q)	66	2,702
XMP.239 (83)	148-161, p-amino-F @ 156 (Q), W @ 158 (F)	30	>2,802
XMP.240 (84)	148-161, p-amino-F @ 152 (G), W @ 158 (F)	55	>2,802
XMP.241 (85)	148-161, L @ 156(Q), W @ 158 (F)	55	>2,161
XMP.242 (86)	148-161, β (2-naphthyl)A _D @ 153 (W), L @ 156 (Q)	52	359
XMP.243 (87)	148-161, β (2-naphthyl)A _D @ 153 (W), W @ 158 (F)	Mixture	716

1 2 2 0 0 0 6 9

TABLE 1 (continued)

	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.244 (88)	148-161, β (2-naphthyl)A _D @ 153 (W), L @ 156 (Q), W @ 158 (F)	43	859
XMP.249 (89)	148-161, G @ 153 (W)	46	1,242
XMP.250 (90)	148-161, L @ 153 (W)	33	536
XMP.251 (91)	148-161, I @ 153 (W)	44	1,289
XMP.252 (92)	148-161, A _D @ 153 (W)	52	1,613
XMP.253 (93)	148-161, V _D @ 153 (W)	51	1,108
XMP.254 (94)	148-161, β -A @ 153 (W)	68	1,040
XMP.255 (95)	148-161, α -Aminobutyric Acid @ 153 (W)	44	392
XMP.256 (96)	148-161, γ -Aminobutyric Acid @ 153(W)	38	b
XMP.257 (97)	148-161, α -Methyl-A @ 153 (W)	44	1,321

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.258 (98)	148-161, t-Butyl-G @ 153 (W)	62	880
XMP.259 (99)	148-161, N-Methyl-G @ 153 (W)	88	2,117
XMP.260 (100)	148-161, N-Methyl-V @ 153 (W)	75	742
XMP.261 (101)	148-161, N-Methyl-L @ 153 (W)	85	867
XMP.262 (102)	148-161, N @ 156 (Q)	68	984
XMP.263 (103)	148-161, E @ 156 (Q)	49	1,197
XMP.264 (104)	148-161, D @ 156 (Q)	60	879
XMP.265 (105)	148-161, R @ 156 (Q)	42	2,996
XMP.266 (106)	148-161, K @ 152(G), V @ 153 (W)	52	984
XMP.267 (107)	148-161, K @ 152 (G), A @ 154 (L)	58	256
XMP.268 (108)	148-161, V @ 153 (W), A @ 154 (L)	48	308

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.269 (109)	148-161, K @ 152 (G), V @ 153 (W), A @ 154 (L)	30	635
XMP.270 (110)	(148-161)+(148-161), L @ 1st 156 (Q)	31	>722
XMP.271 (111)	(148-161)+(148-161), L @ 2nd 156 (Q)	31	>1,995
XMP.272 (112)	(148-161)+(148-161), L @ both 156 (Q)	32	>2,599
XMP.273 (113)	(148-161)+(148-161), F @ 1st 156 (Q)	59	>2,120
XMP.274 (114)	(148-161)+(148-161), F @ 2nd 156 (Q)	40	>2,457
XMP.275 (115)	(148-161)+(148-161), F @ both 156 (Q)	34	b
XMP.283 (116)	148-161, K @ 152 (G), F @ 153 (W), K @ 156 (Q)	36	1,336
XMP.284 (117)	149-161, K @ 152 (G)	60	1,460
XMP.284P ^f (117)	149-161, K @ 152 (G)	96	373

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.285 (118)	149-160, K @ 152 (G)	75	>3,024
XMP.286 (119)	150-161, K @ 152 (G)	61	1,216
XMP.286P ^f (119)	150-161, K @ 152 (G)	80	253
XMP.287 (120)	149-159, K @ 152 (G)	58	>3,509
XMP.288 (121)	150-160, K @ 152 (G)	78	>3,062
XMP.288P ^f (121)	150-160, K @ 152 (G)	94	279
XMP.289 (122)	151-161, K @ 152 (G)	78	1,542
XMP.289P ^f (122)	151-161, K @ 152 (G)	94	658
XMP.290 (123)	149-158, K @ 152 (G)	79	>2,233
XMP.291 (124)	150-159, K @ 152 (G)	55	>5,039
XMP.292 (125)	151-160, K @ 152 (G)	78	>4,463
XMP.293 (126)	152-161, K @ 152 (G)	78	1,156

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.293P ^f (126)	152-161, K @ 152 (G)	95	215
XMP.294 (127)	149-157, K @ 152 (G)	63	>4,634
XMP.295 (128)	150-158, K @ 152 (G)	82	>1,977
XMP.295P ^f (128)	150-158, K @ 152 (G)	c	>2,612
XMP.296 (129)	151-159, K @ 152 (G)	64	>5,573
XMP.297 (130)	152-160 K @ 152 (G)	81	1,817
XMP.297P ^f (130)	152-160 K @ 152 (G)	94	564
XMP.298 (131)	153-161	84	2,628
XMP.298P ^f (131)	153-161	95	1,106
XMP.299 (132)	149-156, K @ 152 (G)	68	>8,768
XMP.300 (133)	150-157, K @ 152 (G)	75	1,957
XMP.300P ^f (133)	150-157, K @ 152 (G)	97	993

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.301 (134)	151-158, K @ 152 (G)	41	b
XMP.302 (135)	152-159, K @ 152 (G)	75	>5,497
XMP.302P ^f (135)	152-159, K @ 152 (G)	98	2,070
XMP.303 (136)	153-160	78	>4,694
XMP.303P ^f (136)	153-160	98	1,307
XMP.304 (137)	154-161	84	>8,290
XMP.305 (138)	149-155, K @ 152 (G)	73	>10,228
XMP.306 (139)	150-156, K @ 152 (G)	62	>10,485
XMP.307 (140)	151-157, K @ 152 (G)	67	>8,345
XMP.308 (141)	152-158, K @ 152 (G)	72	b
XMP.309 (142)	153-159	76	b
XMP.310 (143)	154-160	56	>9,475

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.311 (144)	155-161	77	b
XMP.312 (145)	149-154, K @ 152 (G)	76	>11,120
XMP.313 (146)	150-155, K @ 152 (G)	59	>11,050
XMP.314 (147)	151-156, K @ 152 (G)	73	>13,497
XMP.315 (148)	152-157, K @ 152 (G)	84	>5,069
XMP.315P ^f (148)	152-157, K @ 152 (G)	94	>12,853
XMP.316 (149)	153-158	85	b
XMP.317 (150)	154-159	64	b
XMP.318 (151)	155-160	84	b
XMP.319 (152)	156-161	73	b
XMP.320 (153)	153-157	63	>4,055
XMP.321 (154)	153-157 - K	66	>5,851

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.322 (155)	153-157 - K - K	69	3,488
XMP.323 (156)	K - 153 - 157 - K	63	>4,627
XMP.324 (157)	K - 153 - 157 - K - K	67	894
XMP.325 (158)	K - K - 153 - 157	66	4,135
XMP.326 (159)	K - K - 153 - 157 - K	59	2,182
XMP.327 (160)	K - K - 153 - 157 - K - K	62	353
XMP.327P ^f (160)	K - K - 153 - 157 - K - K	94	630
XMP.330 (161)	153-156	95	b
XMP.331 (162)	† K - K - 153 - 157 - K - K	66	b
XMP.331P ^f (162)	† K - K - 153 - 157 - K - K	97	>3,493
XMP.332 (163)	K _D - K _D - L _D - Q _D - I _D - L _D - W _D - K _D - K _D	64	356
XMP.332P ^f (163)	K _D - K _D - L _D - Q _D - I _D - L _D - W _D - K _D - K _D	98	338

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.333 (164)	K _D - K - 153 - 157 - K - K	62	673
XMP.333P ^f (164)	K _D - K - 153 - 157 - K - K	98	361
XMP.334 (165)	P _D - K - 153 - 157 - K - K	67	1,449
XMP.334P ^f (165)	P _D - K - 153 - 157 - K - K	89	1,065
XMP.335 (166)	P - K - 153 - 157 - K - K	61	871
XMP.335P ^f (166)	P - K - 153 - 157 - K - K	98	1,353
XMP.336 (167)	R - R - 153 - 157 - R - R	22	>7,332
XMP.337 (168)	H - H - 153 - 157 - H - H	70	b
XMP.337P ^f (168)	H - H - 153 - 157 - H - H	94	>3,350
XMP.338 (169)	ORN - ORN - 153 - 157 - ORN - ORN	74	1,194
XMP.338P ^f (169)	ORN - ORN - 153 - 157 - ORN - ORN	96	1,011
XMP.339 (170)	DAB - DAB - 153 - 157 - DAB - DAB	74	2,878

1 2 2 0 0 0 6 9

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.339P ^f (170)	DAB - DAB - 153 - 157 - DAB - DAB	98	2,599
XMP.340 (171)	p-amino-F - p-amino-F - 153 - 157 - p- amino-F - p-amino-F	66	b
XMP.340P ^f (171)	p-amino-F - p-amino-F - 153 - 157 - p- amino-F - p-amino-F	94	b
XMP.341 (172)	PYR - PYR - 153 - 157 -PYR - PYR	76	b
XMP.341P ^f (172)	PYR - PYR - 153 - 157 -PYR - PYR	99	b
XMP.342 (173)	K _D - K _D - 153 - 157 - K _D - K _D	72	1,591
XMP.342P ^f (173)	K _D - K _D - 153 - 157 - K _D - K _D	97	700
XMP.343 (174)	K - K - 153 - 157 - K - K, V @ 153 (W)	69	NT
XMP.344 (175)	K - K - 153 - 157 - K - K, A @ 154 (L)	71	NT
XMP.345 (176)	K - K - 153 - 157 - K - K, A @ 157 (L)	72	NT

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.346 (177)	K - K - 153 - 157 - K - K, p-Amino-F @ 153 (W)	90	NT
XMP.347 (178)	K - K - 153 - 157 - K - K, β (2-naphthyl) A _D @153 (W), L @ 156 (Q)	82	NT
XMP.348 (179)	K - K - K - 153 - 157 - K - K	69	NT
XMP.349 (180)	K - K - 153 - 157 - K - K - K	67	NT
XMP.350 (181)	K - K - K - 153 - 157 - K - K - K	65	NT
XMP.351 (182)	K - K - 153 - 158 - K - K	59	NT
XMP.351P ^f (182)	K - K - 153 - 158 - K - K	98	405
XMP.352 (183)	K - K - 153 - 161	66	NT
XMP.352P ^f (183)	K - K - 153 - 161	98	381
XMP.353 (184)	P - 153 - 161*	66	3,093

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.353P ^f (184)	P - 153 - 161*	99	411
XMP.354 (185)	† P - 153 - 161*	72	NT
XMP.355 (186)	P - 153 - 161	67	2,529
XMP.355P ^f (186)	P - 153 - 161	99	299
XMP.356 (187)	† P - 153 - 161	58	NT
XMP.357 (188)	K - 153 - 160 - P		NT
XMP.358 (189)	K - K - 153 - 160 - P		NT
XMP.359 (190)	C _D - 153 - 161		NT
XMP.360 (191)	K _D - C _D - 154 - 158 - C - K _D		NT
XMP.361 (192)	K _D - C - 154 - 158 - C - K _D		NT
XMP.362 (193)	K _D - K- C - 154 - 158 - C - K - K _D		NT
XMP.363 (194)	K _D - W _D - 154 - 159 - K _D - K _D	68	1,015

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.363P ^f (194)	K _D - W _D - 154 - 159 - K _D - K _D	97	709
XMP.364 (195)	† K _D - W _D - 154 - 159 - K _D - K _D	62	NT
XMP.365 (196)	K _D - W _D - L _D - I _D - Q _D - L _D - F _D - H _D - K _D - K _D	66	1,294
XMP.365P ^f (196)	K _D - W _D - L _D - I _D - Q _D - L _D - F _D - H _D - K _D - K _D	97	544
XMP.366 (197)	† K _D - W _D - L _D - I _D - Q _D - L _D - F _D - H _D - K _D - K _D	54	NT
XMP.367 (198)	K _D - K _D - H _D - F _D - L _D - Q _D - I _D - L _D - W _D - K _D	69	4,641
XMP.368 (199)	† K _D - K _D - H _D - F _D - L _D - Q _D - I _D - L _D - W _D - K _D		NT
XMP.369 (200)	152-161, K @ 152(G), ORN @ 156 (Q)	60	993

2200069

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm ² zone ^a
XMP.370 (201)	† 152-161, K @ 152(G), ORN @ 156 (Q)		NT
XMP.371 (202)	152-161, K @ 152 (G), DAB @ 156 (Q)	74	843
XMP.372 (203)	† 152-161, K @ 152 (G), DAB @ 156(Q)		NT
XMP.373 (204)	† 152-161, K @ 152 (G)		NT

a pmoles of peptide added to well to achieve a 30 mm² zone as determined by PROBIT analysis
b No detectable activity up to 5 µg/well
c NT = not tested
d † = peptide has an acetylated amino terminus; * = peptide has a non-amidated carboxy-terminus
e Abbreviations: X_D refers to a D-amino acid; ORN is ornithine; DAB is diamino butyric acid; PYR is pyridinyl-alanine (free acid)
f "P" refers to XMP peptide purified as described in Example 1

Example 3**IN VITRO AND IN VIVO EFFECT OF ANTI-FUNGAL PEPTIDES
ON A VARIETY OF FUNGAL SPECIES**

5 This example addresses *in vitro* and *in vivo* screening of various Domain III derived peptides for anti-fungal activity against a number of fungal species, including *Candida* species and strains resistant to various anti-fungal agents, in a radial diffusion assay. The example also addresses the effects of combinations of peptide and amphotericin B against *Candida* strain SLU-1.

10 Domain III derived peptides were tested for their fungicidal activity on amphotericin resistant *Candida*. Resistant colonies of *Candida* were isolated using a gradient plate technique. A slanted Sabouraud dextrose agar plate was poured and allowed to harden. The plate was made level and additional agar supplemented with nystatin (Sigma, St. Louis, MO, cat. no. N-3503) at a concentration of 10 $\mu\text{g/mL}$ was poured. Cells from the the CA-1 colony of *Candida albicans* SLU-1 strain described in Example 2 (10^7 cells in a volume of 100 μL) were spread over the plate and incubated at 37°C overnight. Initially, minute colonies were seen and required additional incubation time to achieve the size of wildtype colonies. Eleven colonies were designated SLU-2A through SLU-2K. These colonies were serially passaged in Sabouraud dextrose broth supplemented with increasing concentrations of amphotericin B, after an initial passage with 2 $\mu\text{g/mL}$ amphotericin B. After the final passage in 20 $\mu\text{g/mL}$ amphotericin B, colonies 2G, 2H, 2J and 2K remained viable whereas the wildtype SLU-1 strain remained sensitive to 1 $\mu\text{g/mL}$ amphotericin B. None of the resistant strains demonstrated germ tube formation in fetal bovine serum. In addition, these isolates had a much slower growth rate than SLU-1 and did not form hyphae at 37°C.

25 For the radial diffusion assays, *Candida albicans* SLU-1 were grown as described above and SLU-2G were grown overnight in Sabouraud dextrose broth supplemented with 10 $\mu\text{g/mL}$ amphotericin B and 5 $\mu\text{g/mL}$

30

ceftriaxone at 37°C. Cultures were diluted 1:25 into fresh, unsupplemented broth and allowed to grow for 5 hours at 37°C. Cells were pelleted at 1,500 X g for 5 minutes at 4 °C. Supernatant was decanted and replaced with 5 mL of 10 mM phosphate buffer, pH 7.4. After centrifugation the cell pellets were resuspended with 5 mL phosphate buffer for an OD₅₇₀ determination. One
5 OD₅₇₀ for SLU-1 cells was 3 X 10⁷ CFU/mL and for SLU-2G cells was 5 X 10⁶ CFU/mL.

Cells were added to 10 mL of molten, cooled (~ 45°C) underlayer agarose to a concentration of 1 X 10⁶/mL and the suspension was
10 poured into a level square petri plate with gentle rocking to allow even distribution and solidification to a uniform thickness of about 1 mm. Wells were cut into the hardened agarose with a sterilized, 3 mm diameter punch with vacuum.

Peptides were two-fold serially diluted with D-PBS from a
15 starting concentration of approximately 1 mg/mL. Amphotericin B and nystatin were similarly diluted starting at 100 and 225 µg/mL, respectively. Five µL were added per well and allowed to diffuse at 37°C for 1.5-2.0 hours. Then 10 mL of molten overlayer agarose were added and the plates were incubated inverted at 37°C overnight. Plates were stained with a dilute
20 Coomassie solution, inhibition zones were measured with calipers and net areas were calculated, then converted to pmol values by PROBIT analysis. The results of a representative experiment are shown in Figure 2A for the SLU-1 strain and Figure 2B for the SLU-2G strain. In Figures 2A and 2B, the fungicidal activity is represented for XMP.13 as open circles; for XMP.37 as closed circles; for XMP.97 as open triangles; for XMP.127 as closed
25 triangles; for amphotericin B as open squares; and for nystatin as closed squares. The pmol for a 30 mm² zone of inhibition were calculated to be: for XMP.13, 689 pmol against SLU-1 and 129 pmol against SLU-2G; for
30 XMP.37, 231 pmol against SLU-1 and 75 pmol against SLU-2G; for XMP.97, 670 pmol against SLU-1 and 161 pmol against SLU-2G; for

XMP.127, 935 pmol against SLU-1 and 116 pmol against SLU-2G; for amphotericin B, 36 pmol against SLU-1 and >541 pmol for SLU-2G; and for nystatin, 98 pmol against SLU-1 and >1,215 pmol against SLU-2G. As shown in Figures 2A and 2B, representative Domain III derived peptides
5 XMP.13, XMP.37, XMP.97 and XMP.127 demonstrated fungicidal activity against both the SLU-1 wild type strain and the SLU-2G amphotericin B-resistant strain, with better activity demonstrated against the SLU-2G amphotericin B resistant strain. In contrast, amphotericin B was effective against the original SLU-1 strain but did not kill the SLU-2G resistant cells.
10 These results demonstrate that Domain III derived peptides according to the invention are effective fungicidal agents by a mechanism different from that of amphotericin B.

Further experiments were performed to determine the anti-fungal activity of Domain III derived peptides on commercially-available
15 strains of *Candida* considered resistant to other anti-fungal agents: polyene-resistant *C. albicans* (ATCC Accession No. 38247), 5-fluorocytosine-resistant *C. albicans* (ATCC No. 44373), azole-resistant *C. albicans* (ATCC No. 62342), and ketoconazole-resistant *C. albicans* (ATCC No. 64124). Fungicidal activity of representative peptides XMP.13, XMP.36, XMP.97,
20 XMP.127, and XMP.166 was not reduced on the above strains tested, indicating that the peptides are effective by a mechanism different than that of the other anti-fungal agents.

The anti-fungal activity of Domain III derived peptides was also evaluated *in vitro* against a variety of fungal species, including *Candida*
25 *glabrata*, *Candida krusei*, *Candida lusitanae*, *Candida parapsilosis*, and *Candida tropicalis*. For these experiments, one colony of each of the above-listed *Candida* strains was picked from a Sabouraud's dextrose agar (SDA) plate and inoculated into 5 mL of Sabouraud's dextrose broth (SDB, 2%
30 dextrose and 1% neopeptone) or, for *C. krusei*, Yeast Malt broth (YM, Becton Dickenson, Cockeysville, MD, cat no. BL11405) in 12 mL

polypropylene snap-cap tubes. The tube cultures were incubated overnight with shaking at 37°C.

Cultures were harvested when the OD₅₇₀ of a 1:10 dilution was greater than or equal to the following values: 0.083 for *Candida glabrata*, 0.154 for *Candida krusei*, 0.117 for *Candida lusitaniae*, 0.076 for *Candida parapsilosis*, and 0.192 for *Candida tropicalis*. Cells were centrifuged for 7 minutes in an Eppendorf® microfuge at 3,000 rpm (about 1,500 g). The cell pellet was resuspended in 1 mL PBS and approximately 1 X 10⁷ cells in about 0.5 mL were added to 10 mL of cooled underlay agar (3% SBD, 1% agarose, 0.02% Tween 20, 10 mM sodium phosphate buffer, pH 7.4 at about 45°C.). The suspension was poured into square petri plates, allowed to solidify, and wells cut as described above.

Peptides were two-fold serially diluted with D-PBS from about 20 µL of a starting concentration of approximately 1 mg/mL. Five µL of peptide dilution were added per well and allowed to diffuse for at least about 30 minutes into the agar at 37°C. (to allow complete diffusion). Then 10 mL of molten overlayer agarose (6% SDB, 1% agarose, 10 mM sodium phosphate buffer, pH 7.4 at about 45°C.) were added and the plates were incubated inverted at 37°C overnight. Plates were stained with a dilute Coomassie solution, inhibition zones were measured with calipers and net areas were calculated, then converted to pmole values by PROBIT analysis. The results of a representative experiment are shown in Table 2. Exemplary Domain III derived peptides XMP.13P, XMP.97P, XMP.127P, XMP.166P, XMP.286P, XMP.327P, XMP.331P, XMP.332P, XMP.333P and XMP.337P demonstrated some fungicidal activity against at least several of the *Candida* strains tested. These results demonstrate that Domain III derived peptides according to the invention are effective fungicidal agents in a broad spectrum against a variety of *Candida* species.

TABLE 2

Anti-fungal activity: pmol/30 mm² zone^{a,d}

	<i>Candida albicans</i>	<i>Candida glabrata</i>	<i>Candida krusei</i>	<i>Candida lusitanae</i>	<i>Candida parapsilosis</i>	<i>Candida tropicalis</i>
XMP.13P ^e	2,233	1,022	1,747	746	1,502	452
XMP.97P ^e	2,019	1,786	907	900	868	193
XMP.127P	2,144	779	878	551	711	373
XMP.166	>3,079	2,100	3,240	1,133	1,199	864
XMP.286P ^e	NT ^c	1,843	1,558	1,235	1,134	606
Amphotericin B	11	<17	120	35	91	108
XMP.327P ^e	5,108	>6,295	3,327	120	119	2,598
XMP.331P ^e	b	b	>5,467	1,500	1,451	b

TABLE 2 (continued)

Anti-fungal activity: pmol/30 mm ² zone ^{a,d}						
	<i>Candida albicans</i>	<i>Candida glabrata</i>	<i>Candida krusei</i>	<i>Candida lusitanae</i>	<i>Candida parapsilosis</i>	<i>Candida tropicalis</i>
XMP.332P ^e	3,931	2,190	2,802	<219	170	866
XMP.333P ^e	5,191	4,040	4,101	174	209	2,894
XMP.337P ^e	b	b	5,339	6,928	b	b
a	pmol of peptide added to well to achieve a 30 mm ² zone as determined by PROBIT analysis					
b	No detectable activity up to 5 μg/well					
c	NT = not tested					
d	Actual pmol values obtained are dependent on assay conditions; values in this Table for <i>C. albicans</i> higher than those presented in Table 1 due to higher effective concentration of agarose during incubation					
e	"P" refers to XMP peptide purified as described in Example 1					

The effects of combinations of peptide and amphotericin B against *Candida* strain SLU-1 were studied. For these experiments, *Candida albicans* SLU-1 was grown and assayed in a broth dilution assay as described in Example 2, except that peptide alone, amphotericin B alone, or combinations of peptide and amphotericin B were incubated with the fungal cells for testing.

The results of such an assay using representative peptide XMP.97, alone or in combination with amphotericin B, are shown in Figure 3. In Figure 3, the fungicidal activity of combinations of XMP.97 and amphotericin B are represented for the XMP.97 concentrations shown and concentrations of amphotericin B of 0.047 $\mu\text{g/ml}$ (open squares); 0.074 $\mu\text{g/ml}$ (closed triangles); 0.188 $\mu\text{g/ml}$ (open triangles); 0.375 $\mu\text{g/ml}$ (closed circles); and 0.750 $\mu\text{g/ml}$ (open circles). The activity of XMP.97 alone is represented by the closed squares. Both XMP.97 and amphotericin B are each effective alone at certain concentrations as anti-fungal agents. The combination of peptide and amphotericin B does not result in inhibition (as it would if the two drugs were antagonistic), but rather results in decreasing the amount of both anti-fungal agents required for maximum killing. In particular, concurrent administration of this Domain III derived peptide with an anti-fungal agent, such as amphotericin B, achieved an improved therapeutic effectiveness through reducing the concentration of amphotericin B required to eradicate or inhibit fungal growth. Because the use of amphotericin B has been limited by its systemic toxicity, lowering the concentration of such an anti-fungal agent required for therapeutic effectiveness can reduce toxicity, and thus may allow wider use of this agent.

The anti-fungal activity of Domain III derived peptides may also be evaluated *in vivo* in animal models for a variety of fungal species, including *Cryptosporidium parvum*, *Cryptococcus neoformans* and *Histoplasma capsulatum*. Animal models for *C. parvum*, sponsored by contract resources from the National Institute of Allergy and Infectious Diseases, include severe

combined immunodeficiency (SCID) mouse models and a colostrum-deprived SPF piglet model.

Example 4

5 *IN VIVO* ANTI-FUNGAL EFFECT OF PEPTIDES 10 IN MICE WITH SYSTEMIC *CANDIDA* INFECTION

 This example addresses the *in vivo* anti-fungal effect of Domain
 III derived peptides in mitigating the total mortality or mortality rate of mice
 systemically infected with *Candida albicans*. Peptides that had been screened
10 for anti-fungal activity in the radial diffusion and broth assays described in
 Example 2 were prepared and purified as described in Example 1.

 Groups of 15 male DBA/2J mice at age 6-8 weeks (Jackson
 Laboratory, Bar Harbor, ME) were inoculated with 1.24×10^5 *C. albicans*
 (SLU-1 strain as described in Example 2) by intravenous injection into the tail
15 vein. Cells were prepared for animal injection as follows. A single colony
 was selected and used to inoculate a 5 mL tube of Sabouraud dextrose broth.
 Incubation was at 30°C with shaking to allow aeration for a period of 15-18
 hours. Four mL of the overnight culture were added to 100 mL of fresh
 Sabouraud dextrose broth (1:25 dilution) and incubated for 4 hours. The 100
20 mL culture was pelleted at 1,500 X g for 5 minutes. Cells were washed twice
 by adding 20 mL D-PBS, vortexing and re-centrifuging. Cells were collected
 in one tube and a sample is diluted 1:10 to be measured by OD₅₇₀ (1 OD unit
 = 3×10^7 CFU/mL). The cells were diluted to the desired dose in D-PBS
 and kept at 4°C until used. Doses were confirmed by performing serial ten-
25 fold dilutions and plating 50 μ l per dilution on Sabouraud dextrose agar.
 Colonies were counted the following day after overnight incubation at 37°C.
 A 500 mL culture yielded approximately 1×10^9 CFU/mL.

30 A *Candida* inoculation of approximately 1×10^5 cells resulted
 in an LD₈₀ over 28 days in this model. Immediately after fungal challenge,
 the mice were intravenously injected via the tail vein with a 0.1 mL volume

of 10 mg/kg XMP.36, 5 mg/kg XMP.97, 10 mg/kg XMP.102, 1 mg/kg amphotericin B (Sigma, St. Louis, MO), or phosphate buffered saline (PBS) as a control. Treatment with the same amounts of peptides, amphotericin B or PBS was repeated at Day 2 and Day 4 (except that the second dose of XMP.36 was given at a dose of 5 mg/kg). Mice were monitored twice daily for mortality until termination of the study at Day 28. The mortality data, displayed in Figure 4, show that 100% of the mice treated with amphotericin B survived, 53% of mice treated with XMP.97 survived ($p < 0.05$ compared to control), 33% of mice treated with XMP.36 survived, 27% of mice treated with XMP.102 survived, and 20% of mice treated with PBS survived until Day 28. In Figure 4, the symbol "X" represents survival after treatment with amphotericin B; open squares, treatment with XMP.97; open circles, treatment with XMP.36; open diamonds, treatment with XMP.102; and open triangles, treatment with buffer. Statistical significance was evaluated using the Lifetest Survival Curve analysis. [Lawless, *Statistical Models and Methods for Lifetime Data*, John Wiley & Sons, New York (1982).] The duration and almost linear decline in survival is analogous to human opportunistic candidiasis.

In additional 3-dose studies, groups of 15 mice were injected with a fungal challenge of 0.5×10^5 *Candida* cells, prepared for injection as described above, followed by treatment at Day 0, Day 2 and Day 5 with a 0.1 mL volume of 10 mg/kg XMP.127, 5 mg/kg XMP.13, 5 mg/kg XMP.37, 1 mg/kg amphotericin B, or PBS as a control. The mortality data are displayed in Figure 5; 100% of the mice treated with amphotericin B survived, 67% of mice treated with XMP.127 survived ($p < 0.05$ compared to control), 33% of mice treated with XMP.37 survived, 20% of mice treated with XMP.13 survived, and 33% of mice treated with PBS survived until Day 28. In Figure 5, the symbol "X" represents survival after treatment with amphotericin B; open circles, treatment with XMP.127; filled triangles, treatment with buffer;

open squares, treatment with XMP.37; open triangles, treatment with XMP.13.

In these 3-dose studies, amphotericin B was completely protective, as expected. The effect of XMP.102, a control peptide without anti-fungal activity as determined by a radial diffusion assay as described in Example 2, was no different from PBS. The data demonstrate that administration of peptides XMP.97 and XMP.127 to mice challenged systemically with *C. albicans* unexpectedly provided a significant reduction in mortality compared with buffer-treated controls.

Further studies to determine the effectiveness of anti-fungal peptides were performed at an increased dosing regimen (6 doses rather than 3 doses as described above). Groups of 9 week-old male DBA/2J mice were inoculated with concentrations of 2.7×10^5 *Candida* cells (prepared as described above) by intravenous injection in the tail vein. Immediately after fungal challenge, the mice were treated with a 0.1 mL volume of 10 mg/kg XMP.284, 1 mg/kg amphotericin B or PBS as a control at Day 0, Day 2, Day 4, Day 7, Day 9 and Day 11. All amphotericin B-treated animals were protected. The results for XMP.284 (closed circles) and PBS control (open circles) are displayed in Figure 6. The mortality data showed that only one of the PBS-treated animals survived injection with 2.7×10^5 *Candida* at Day 6 through Day 24 (6% survival), however, XMP.284 protected 13 animals (87% survival) at Day 6 and 3 animals (33% survival) at Day 24.

Studies were also performed to determine the effectiveness of representative anti-fungal peptides in cyclosporin A-immunosuppressed mice systemically infected with *Candida albicans* SLU-1. Groups (15 animals/group) of 9 week-old male DBA/2J mice were immunosuppressed by pretreatment with 10 mg/kg (Day-1) of cyclosporin A administered by intraperitoneal injection. One day later (Day 0), the mice were inoculated with 2×10^5 *Candida* cells by intravenous injection in the tail vein. Immediately after fungal challenge, the mice were treated with a 0.1 mL

volume of 10 mg/kg XMP.284, 10 mg/kg XMP.127, or PBS as a control. Cyclosporin A injections were repeated at Day 1, Day 3, Day 7, and Day 9. XMP.284, XMP.127 or PBS injections were repeated at Day 2, Day 4, Day 6, Day 8 and Day 10. All amphotericin B-treated animals were protected. The results displayed in Figure 7 of the mortality data after treatment with XMP.127 (closed triangles), XMP.284 (open squares) and PBS control (open circles) show that the immunosuppressed mice are more susceptible to *Candida* infection as expected. However, XMP.284 and to a lesser extent XMP.127, provided protection against the infection as measured by increased survival compared with PBS controls.

Further *in vivo* experiments with or without cyclosporin A immunosuppression are performed to confirm the *in vitro* anti-fungal activity of peptides as described in Example 3 on strains of *Candida* considered resistant to other anti-fungal agents: polyene-resistant *C. albicans* (ATCC Accession No. 38247), 5-fluorocytosine-resistant *C. albicans* (ATCC No. 44373), azole-resistant *C. albicans* (ATCC No. 62342), and ketoconazole-resistant *C. albicans* (ATCC No. 64124).

Example 5

SERUM STABILITY ASSAYS

This example addresses the serum stability of Domain III derived peptides and the effect of serum degradation using HPLC and bioassay.

For these serum stability experiments, peptides were prepared by solid phase peptide synthesis and purified to 94% or greater purity as described in Example 1. Blood was collected from metaphane anesthetized rats by aortic bleed into Vacutainer™ tubes and allowed to clot at room temperature for approximately 30 minutes, then centrifuged at 3000 rpm (about 1000 X g) for 10 minutes at room temperature and the serum aspirated. In addition, frozen human serum (North American Biologics, Inc., Miami,

FL, cat. no. 2140, lot no. 94115) was thawed at room temperature and filtered through a 0.45 μ m membrane before use.

5 A 1 mg/mL solution of an exemplary XMP peptide to be tested was added to an equal volume of either rat or human serum described above and maintained at 37°C. At 0, 1, 2, and 4 hours, 100 μ L were removed and processed by solid phase extraction for HPLC analysis as follows. Serum samples were prepared for HPLC using C-18 Sep-Pak® cartridges (1 mL
10 cartridge with 100 mg of sorbent, Waters Corp., Milford, MA). One hundred μ L of serum sample were added to an equal volume of 1% TFA and mixed for 30 seconds on a Vortex® mixer. The sample was then applied to a C-18 Sep-Pak cartridge that had been conditioned by washing with 1 mL of methanol followed by
15 1 mL Milli-Q® water. Weakly retained components were eluted by washing with 1 mL of 0.1% TFA. The bound peptide was eluted with two volumes of 250 μ L 80% acetonitrile/0.065% TFA.

20 The material eluted from the Sep-Pak cartridge was analyzed on a Michrom Ultrafast Microprotein Analyzer equipped with a 150 mm X 1 mm, 5 μ particle, 300 Å pore C-8 Zorbax column. The column oven was set to 40°C., the flow rate was 100 μ L/minute, and injection volumes were typically 5-10 μ L. HPLC was performed using 5% acetonitrile/0.1% TFA in
25 water as mobile phase A, and 80% acetonitrile/0.065% TFA as mobile phase B. The eluate was monitored spectrophotometrically at 214 nm. Peptide standards were dissolved in mobile phase A at 0.1 mg/mL. The gradient was 25-35% B/10 minutes followed by a 5 minute wash step of 100%
30 B and reequilibration at 25% B for 10 minutes.

35 The peptides identified and purified after serum incubation as described above were subjected to N-terminal peptide sequencing performed on an Applied Biosystems Model 477A/120A sequencer and to electrospray ionization mass spectrometry (ESI/MS) performed using a VG Biotech Bio-Q® Mass Spectrometer. In addition, the peptides identified and purified after serum incubation as described above were also tested for their anti-fungal

activity in a radial diffusion bioassay with *Candida albicans* SLU-1 strain as described in Example 2.

For these experiments, representative Domain III derived peptides XMP.97, XMP.327, XMP.332 and XMP.333 were used. The serum stability of each differed substantially. For example, XMP.97 was degraded in serum with a half-life of 59 minutes under the described assay conditions. Two metabolites of XMP.97 were detected and were determined to be cleavage products where the cleavage at the amino terminus yielded peptides shortened by either one or two amino acids. The degradation products and kinetics were similar for commercially obtained human serum or freshly prepared rat serum. Other metabolic products of XMP.97 were presumably present but in concentrations below detection limits.

The chemical changes observed after serum incubation of a peptide were generally accompanied by a loss in activity as determined in the radial diffusion assay with *Candida*. For example, XMP.327 was degraded with a serum half-life of 40 minutes under the described HPLC assay conditions. The serum half-life of XMP.327 as determined by anti-fungal activity in the radial diffusion assay was 43 minutes. In other cases, there may be a difference between the rate of disappearance of anti-fungal activity and the rate of peptide disappearance, indicating that certain metabolites may have activity.

The enzymes responsible for peptide degradation were not specifically identified in these experiments. However, aminopeptidases present in serum are capable of removing one or more residues from the N-terminus of peptides. [See, e.g., Hooper, N.M., Ectopeptidases, in Biological Barriers to Protein Delivery, pp.23-50, eds., Audus and Raub, Plenum Press, New York, 1993]. Aminopeptidase N (EC 3.4.11.2), for example, has a broad substrate specificity, releasing the N-terminal amino acid from unblocked peptides. Based on sites of potential hydrolysis, peptides can be designed to minimize certain degradation pathways. Serum degradation at

specific amino acids within a peptide may be avoided by incorporation of D-amino acids or other atypical amino acids, and/or by cyclization to prevent protease recognition.

5 In additional studies, peptides were designed to have increased serum stability. For example, peptides were synthesized using one or more D-amino acids. Also, peptides were synthesized and then their N-terminus was acetylated as described in Example 1. For example, XMP.333 was synthesized having the same amino acid sequence as XMP.327, except that the amino-terminal lysine residue used for synthesis was a D-amino acid. When
10 XMP.333 was tested, its serum half-life as determined in the radial diffusion assay was 130 minutes (as compared with 43 minutes for XMP.327). These results indicate that a single D-amino acid at the N-terminus prevents some degradation and increases the half-life of the peptide.

Peptide constructs can be prepared with increased half-life, but
15 may not maintain the same *in vitro* activity. For example, XMP.327 had a serum half-life of 43 minutes and activity in radial diffusion of 353 pmol (see Table 1). Peptide XMP.331 having the same amino acid sequence of XMP.327 but having an acetylated N-terminus, had an increased serum half-life of 280 minutes as detected by HPLC analysis, but a decreased activity of
20 > 3,493 pmol (see Table 1) as compared with the non-acetylated XMP.327. However, even with decreased *in vitro* activity, such a peptide may have increased efficacy *in vivo* due to its increased stability.

Other peptide constructs can be prepared with not only significantly increased stability but also with maintained anti-fungal activity
25 in the radial diffusion assay. For example, XMP.332 was synthesized using all D-amino acids and is the inverse sequence of XMP.327. Such a "retro-D" peptide should be resistant to serum enzymes that recognize and hydrolyze the peptide bond between L-amino acids. In fact, XMP.332 did not show any
30 decrease in activity or decrease in peptide concentration over a 6 hour period of serum incubation. Such a peptide construct, which can maintain the *in*

vitro equivalent molar activity to its L-amino acid peptide counterpart and shows increased serum half-life, may have increased efficacy *in vivo*.

Example 6

5

STRUCTURE/FUNCTION STUDIES

This example addresses the design and assay of anti-fungal peptides for structural motif and minimum functional sequence analysis.

As shown in Examples 2, 3, and 4 above, XMP.97 was determined to have significant *in vitro* activity against *C. albicans* and significant *in vivo* activity in a mouse systemic candidiasis model. The sequence was derived from XMP.13 with a lysine substitution for glycine at position 152 in the BPI sequence. As shown in Example 5, sequential N-terminal amino acid removal was observed when the peptides, including XMP.97, were incubated with serum. The 13 amino acid peptide XMP.284 (SKVKWLIQLFHKK-amide; SEQ. ID. NO:117) was synthesized, purified (97%) and tested for anti-fungal activity. The *in vitro* activity was surprisingly not appreciably diminished (see Table 1). A deletion series of 35 peptides was generated from this starting sequence. All possible N- and C-terminal deletion 12-mers through 6-mers (XMP.285-XMP.319) were synthesized as shown in Table 3 below.

Crude peptides were assayed for an initial purity as described in Example 1 and for *in vitro* activity with the radial diffusion fungicidal assay as described in Example 2. The nmol value shown in Table 3 represents a calculated value (log titration curve) for the number of nanomoles required to achieve a net 30 mm² zone in the assay. In purifying XMP.97 and XMP.284, a significant change was observed in the pmol value upon purification. The magnitude of change was larger than observed with other crude peptides and was likely due to removal of inactive peptide impurities. Thus, final comparisons were made using peptides purified as described in Example 1, and preferably assayed on the same day.

The most active crude peptides were purified by HPLC and re-assayed. The results are shown in Table 3. From this analysis, as demonstrated by Table 3, XMP.293 was the smallest peptide with an increase in molar activity relative to peptide XMP.97. XMP.297 was also equivalent
5 to XMP.284 in activity. Interestingly, XMP.298 was within two-fold of XMP.297. Activity was demonstrable even with 6 amino acid peptides, such as XMP.315, however, this level of activity was decreased by about 3 orders of magnitude compared with the activity of the starting sequence.

These data demonstrate that one group of Domain III derived
10 peptides of the invention are described and defined by a structural motif consisting of a core of 4 to 6, preferably 5 to 6, amino acids where the core contains one neutral hydrophilic residue in the middle of hydrophobic amino acids, and where the core is bounded or flanked at the N- and/or C-terminus by cationic amino acids. Preferred core sequences include: L1QL, IQLF,
15 WLIQF, LIQLF and WLIQLF. Preferred cationic amino acids include: K (most preferred), R, H, ornithine (ORN) and diaminobutyric acid (DAB). Peptides with such a motif possess optimal activity. Activity was observed, but was somewhat diminished, when the peptide contained all of the cationic residues on the C-terminus (*e.g.*, XMP.298) or on the N-terminus (*e.g.*,
20 XMP.300) of the core. Peptides XMP.320 - XMP.368 were designed and prepared consistent with this motif, and provide additional support for the structural motif and minimum functional characterization sequence of anti-fungal peptides according to the invention.

TABLE 3

Length in a.a. ^a	Peptide	MW	AMINO ACID SEQUENCE													Plate Assay (nmol) ^b	Crude Purity (%)	Plate Assay (nmol) ^c
			148	149	150	151	152 ^{mb}	153	154	155	156	157	158	159	160	161		
14	97	1782	K	S	K	V	K	W	L	I	Q	L	F	H	K	K	68	0.304
13	284	1654	.	S	K	V	K	W	L	I	Q	L	F	H	K	K	60	0.373
12	285	1526	.	S	K	V	K	W	L	I	Q	L	F	H	K	.	75	
	286	1527	.	.	K	V	K	W	L	I	Q	L	F	H	K	K	61	0.253
11	287	1398	.	S	K	V	K	W	L	I	Q	L	F	H	.	.	58	
	288	1439	.	.	K	V	K	W	L	I	Q	L	F	H	K	.	78	0.279
	289	1439	.	.	.	V	K	W	L	I	Q	L	F	H	K	K	78	0.68
10	290	1261	.	S	K	V	K	W	L	I	Q	L	F	.	.	.	79	
	291	1311	.	.	K	V	K	W	L	I	Q	L	F	H	.	.	55	
	292	1311	.	.	.	V	K	W	L	I	Q	L	F	H	K	.	78	
	293	1340	.	.	.	.	K	W	L	I	Q	L	F	H	K	K	78	0.215

TABLE 3 (continued)

Length in a.a. ^a	Peptide	MW	AMINO ACID SEQUENCE													Plate Assay (nmol) ^b	Crude Purity (%)	Plate Assay (nmol) ^c
			148	149	150	151	152 ^{sub}	153	154	155	156	157	158	159	160	161		
9	294	113	.	S	K	V	K	W	L	I	Q	L	.	.	.	.	63	>4.634
	295	1174	.	.	K	V	K	W	L	I	Q	L	F	.	.	.	82	>1.977
	296	1183	.	.	.	V	K	W	L	I	Q	L	F	H	.	.	.64	>5.573
	297	1212	.	.	.	.	K	W	L	I	Q	L	F	H	K	.	81	1.817
	298	1212	.	.	.	.	.	W	L	I	Q	L	F	H	K	K	84	2.628
8	299	1000	.	S	K	V	K	W	L	I	Q	.	.	.	.	.	68	>8.768
	300	1026	.	.	K	V	K	W	L	I	Q	L	.	.	.	.	75	1.957
	301	1045	.	.	.	V	K	W	L	I	Q	L	F	.	.	.	41	--
	302	1083	.	.	.	.	K	W	L	I	Q	L	F	H	.	.	75	>5.497
	303	1083	.	.	.	.	.	W	L	I	Q	L	F	H	K	.	78	>4.694
	304	1025	.	.	.	.	.	.	L	I	Q	L	F	H	K	K	84	>8.290

TABLE 3 (continued)

Length in a.a. ^a	Peptide	MW	AMINO ACID SEQUENCE													Plate Assay (nmol) ^b	Crude Purity (%)	Plate Assay (nmol) ^c
			148	149	150	151	152 ^{mb}	153	154	155	156	157	158	159	160	161		
7	305	872.1	.	S	K	V	K	W	L	I	.	.	.	.	.	.	73	> 10.228
	306	913.2	.	.	K	V	K	W	L	I	Q	.	.	.	.	.	62	> 10.485
	307	898	.	.	.	V	K	W	L	I	Q	L	.	.	.	.	67	> 8.345
	308	946	.	.	.	.	K	W	L	I	Q	L	F	.	.	.	72	--
	309	955	.	.	.	.	.	W	L	I	Q	L	F	H	.	.	76	--
	310	897	.	.	.	.	.	.	L	I	Q	L	F	H	K	.	56	> 9.475
	311	912	.	.	.	.	.	.	.	I	Q	L	F	H	K	K	77	--

Length in a.a. ^a	Peptide	MW	AMINO ACID SEQUENCE													Plate Assay (nmol) ^b	Crude Purity (%)	Plate Assay (nmol) ^c
6	312	759	148	149	150	151	152 ^{mb}	153	154	155	156	157	158	159	160	161		
			.	S	K	V	K	W	L	.	.	.	.	.	.	.	76	
	313	785	.	.	K	V	K	W	L	I	.	.	.	.	.	.	59	
	314	785	.	.	.	V	K	W	L	I	Q	.	.	.	.	.	73	
	315	799	.	.	.	.	K	W	L	I	Q	L	.	.	.	.	84	>12.853
	316	818	.	.	.	.	.	W	L	I	Q	L	F	.	.	.	85	inactive to 11.5
	317	769	.	.	.	.	.	.	L	I	Q	L	F	H	.	.		
	318	784	.	.	.	.	.	.	.	I	Q	L	F	H	K	.		
	319	799	.	.	.	.	.	.	.	.	Q	L	F	H	K	K		

^a a.a. = amino acids

^b crude peptide activity

^c pure peptide activity

Example 7

LPS NEUTRALIZATION ACTIVITY OF ANTI-FUNGAL PEPTIDES

5 This example addresses the *in vitro* and *in vivo* LPS neutralizing activity of Domain III derived peptides.

10 An *in vitro* LPS neutralization screening assay for evaluation of Domain III derived peptides was developed (as described in co-owned U.S. Patent No. 5,652,332) which provides both a measure of efficacy of each peptide (EC_{50}) and of the toxicity/growth inhibition of each peptide (IC_{50}). This sensitive assay for inhibition of cellular proliferation in mouse cells treated with LPS can also be utilized for quantitation of LPS levels in human plasma upon development of a standard curve.

15 In this assay, mouse RAW 264.7 cells (ATCC Accession No. T1B71), maintained in RPMI 1640 medium (GIBCO), supplemented with 10mM HEPES buffer (pH 7.4), 2mM L-glutamine, penicillin (100U/mL), streptomycin (100 μ g/mL), 0.075% sodium bicarbonate, 0.15M 2-mercaptoethanol and 10% fetal bovine serum (Hyclone, Inc., Logan, UT), were first induced by incubation in the presence of 50U/mL recombinant mouse γ -interferon (Genzyme, Cambridge, MA) for 24h prior to assay. 20 Induced cells were then mechanically collected and centrifuged at 500 x g at 4°C and then resuspended in 50mL RPMI 1640 medium (without supplements), re-centrifuged and again resuspended in RPMI 1640 medium (without supplements). The cells were counted and their concentration 25 adjusted to 2×10^5 cells/mL and 100 μ L aliquots were added to each well of a 96-well microtitre plate. The cells were then incubated for about 15 hours with *E. coli* O113 LPS (Control Standard, Assoc. of Cape Cod, Woods Hole, MA), which was added in 100 μ L/well aliquots at a concentration of 1 ng/mL 30 in serum-free RPMI 1640 medium (this concentration being the result of titration experiments in which LPS concentration was varied between 50

pg/mL and 100 ng/mL). This incubation was performed in the absence or presence of peptides in varying concentrations between 25ng/mL and 50 μ g/mL. Recombinant human rBPI₂₁, also designated rBPI₂₁ Δ cys, which is rBPI 1-193, with alanine substituted at position 132 for cysteine [see co-owned U.S. Patent No. 5,420,019] was used as a positive control at a concentration of 1 μ g/mL. Cell proliferation was quantitatively measured by the addition of 1 μ Ci/well [³H]-thymidine 5 hours after the time of initiation of the assay. After the 15-hour incubation, labeled cells were harvested onto glass fiber filters with a cell harvester (Inotech Biosystems, INB-384, Sample Processing and Filter Counting System, Lansing, MI.).

The LPS-mediated inhibition of RAW 264.7 cell proliferation is dependent on the presence of LBP, as added to the reaction mixture either as a component of serum or as recombinant LBP (at a concentration of 1 μ g/mL). Different patterns of peptide behavior are observed in the assay. The Domain III derived anti-fungal peptides with LPS-neutralizing activity according to the present invention generally did not exhibit an IC₅₀ at the concentrations tested, unlike other XMP peptides including LPS-neutralizing peptides that are not anti-fungal, as described in co-owned U.S. Patent Nos. 5,733,872 and 5,652,332. For example, XMP.5 displayed an EC₅₀ (*i.e.*, the peptide concentration at which the growth inhibitory effect of LPS was reversed by 50%) of 5.3 ± 0.6 μ g/mL; however, an IC₅₀ (*i.e.*, the peptide concentration at which RAW cell growth was inhibited by 50% from the value without added LPS or peptide) was not observed at the concentrations tested. The results of a representative assay of exemplary Domain III derived anti-fungal peptides are shown in Figure 8. The LPS-neutralizing activities of the purified anti-fungal peptides XMP.327 (open squares), XMP.332 (closed squares), XMP.333 (open triangles) and XMP.337 (closed triangles) are shown in Figure 8. Also shown as a positive control is the activity of rBPI₂₁. Results from representative peptides tested with this assay are shown in Table 4.

TABLE 4

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>In Vitro</i> LPS Neutralization	
			EC ₅₀ ^a µg/ml	IC ₅₀ ^b µg/ml
XMP.97P (31)	148-161, K @ 152 (G)	98	3.69 ± 0.46	>25
XMP.127 (47)	148-161, F @ 153 (W)	63	10.77 ± 1.34	NA
XMP.284P (117)	149-161, K @ 152 (G)	96	4.72 ± 0.08/ 3.57 ± 0.09	NA/ >50
XMP.286P (119)	150-161, K @ 152 (G)	80	4.68 ± 0.26	NA
XMP.288P (121)	150-160, K @ 152 (G)	94	0.87 ± 0.06	>25
XMP.295P (128)	150-158, K @ 152 (G)	NT	3.69 ± 0.12	>25
XMP.303P (136)	153-160	98	11.79 ± 0.85	NA
XMP.327P (160)	K - K - 153 - 157 - K - K	94	11.92 ± 0.09	NA
XMP.330 (161)	153-156	95	>50	NA
XMP.331P (162)	† K - K - 153 - 157 - K - K	96	14.11 ± 0.35	NA

TABLE 4 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	EC ₅₀ ^a µg/ml	In Vitro LPS Neutralization	IC ₅₀ ^b µg/ml
XMP.332P (163)	K _D - K _D - L _D - Q _D - L _D - L _D - W _D - K _D - K _D	98	5.65 ± 0.16	NA	NA
XMP.333P (164)	K _D - K - 153 - 157 - K - K	98	>25	NA	NA
XMP.334P (165)	P _D - K - K - 153 - 157 - K - K	89	NA	NA	NA
XMP.335P (166)	P - K - 153 - 157 - K - K	98	NA	NA	NA
XMP.336P (167)	R - R - 153 - 157- R - R	97	NA	NA	NA
XMP.337P (168)	H - H - 153 - 157 - H - H	94	>50	NA	NA
XMP.338 (169)	ORN - ORN - 153 - 157 - ORN - ORN	74	>25	NA	NA
XMP.339P (170)	DAB - DAB - 153 - 157 - DAB - DAB	98	NA	NA	NA

TABLE 4 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	EC ₅₀ ^a µg/ml	In Vitro LPS Neutralization IC ₅₀ ^b µg/ml
XMP.340P (171)	p-amino-F - p-amino-F - 153 - 157 - p-amino-F - p- amino-F	94	>50	NA
XMP.341P (172)	PYR - PYR - 153 - 157 - PYR - PYR	99	>50/ >50	NA/NA
XMP.342 (173)	K _D - K _D - 153 - 157 - K _D - K _D	72	>50	NA
XMP.342P (173)	K _D - K _D - 153 - 157 - K _D - K _D	97	NA	NA
XMP.351P (182)	K - K - 153 - 158 - K - K	98	8.47 ± 0.71	NA
XMP.352P (183)	K - K - 153 - 161	98	2.34 ± 0.38	NA
XMP.353P (184)	P - 153 - 161*	99	4.42 ± 0.56	NA
XMP.355P (186)	P - 153 - 161	99	1.08 ± 0.05	NA

TABLE 4 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>In Vitro</i> LPS Neutralization EC ₅₀ ^a µg/ml	IC ₅₀ ^b µg/ml
XMP.363P (194)	K _D - W _D - 154 - 159 - K _D - K _D	97	>50	NA
XMP.365P (196)	K _D - W _D - L _D - I _D - Q _D - L _D - F _D - H _D - K _D - K _D	97	0.52 ± 0.07	>25

a NA for EC₅₀ means no evidence neutralization of LPS at up to 50 µg/ml
b NA for IC₅₀ means no evidence of decreased RAW cell growth at up to 50 µg/ml
c NT = not tested

Domain III derived peptides are also tested for LPS neutralizing efficacy in an *in vivo* mouse experimental endotoxemia model. Groups of 15 mice were administered an intravenous injection of endotoxin (*E. coli* O111:B4, Sigma Chemical Co., St. Louis, MO) at a LD₉₀ dosage of 20 mg/kg. This was followed by a second intravenous injection of the peptide to be tested. Injections of saline were used in negative control mice. The animals were observed for 7 days and mortality recorded. The efficacy of the peptides was measured by a decrease in endotoxemia-associated mortality in peptide-injected mice as compared with control mice. XMP.284 is a representative peptide active in this murine model. As shown in Figure 7, significant protection was observed with a 0.5 mg/kg dose of XMP.284, while at a 1 mg/kg dose, 14 of 15 animals were protected, and a 3 mg/kg dose was effective to protect all treated animals (100% survival). No animals survived in the saline control group.

Example 8

PEPTIDE FORMULATIONS

This example addresses peptide formulations. A representative Domain III derived peptide XMP.284 was evaluated for stability in liquid formulations containing buffered saline solutions and to elucidate breakdown mechanisms, if any, that might be common to such peptides.

The lyophilized peptide was dissolved to a concentration of 1 mg/mL in three different buffers. The three formulation buffers used were (a) 10 mM solution acetate, 150 mM sodium chloride pH 4, (b) 10 mM sodium acetate, 150 mM sodium chloride pH 5 and (c) 10 mM sodium acetate, 150 mM sodium chloride pH 6. The formulated peptide samples were incubated at 4°C and 37°C. At each time point, samples were withdrawn from each vial and assayed by C18 reverse phase HPLC, absorbance at 280 nm, and SDS-PAGE. The study was conducted for 50 days.

A 0.46 x 25 cm Vydac® C18 column (cat no. 218TP54) was used on a Shimadzu® HPLC system. The column was run in binary gradient mobile phases: A = Water + 0.05% TFA, B = acetonitrile + 0.05% TFA. Chromatographic conditions were as follows: wavelength = 229 nm; flowrate = 1 mL/min; injection volume = 50 µL; run time = 37 minutes; gradient = 20% B to 40% B in 20 minutes; AUFS = 0.1 for XMP.284; concentration of sample = 3.5 µg per 50 µL injection volume. In preparation for the C18 assay, the samples withdrawn from the vials were diluted 16-fold with 0.05% TFA in water. All samples were filtered through Acrodisc® 4 prior to analysis.

Samples were analyzed by SDS polyacrylamide gel electrophoresis, run on Novex® 10-20% tricine precast gels (Novex, La Jolla, CA, EC6625). Samples were mixed with non-reducing sample loading buffer (Novex LC1676, 2x) and heated at 95°C. for two minutes. After cooling, samples were run on the gel and the gels were stained with Coomassie Blue. In addition, samples were analyzed spectrophotometrically. For this, samples withdrawn at each time point were diluted 6-fold with Millipore® water and absorbance was measured at 280 nm and scanning from 210 nm to 340 nm using a Shimadzu UV 160 spectrophotometer. All samples were filtered prior to absorbance measurement(s).

XMP.284 was soluble in water and unbuffered saline. XMP.284 was also soluble in 10 mM sodium phosphate, 150 mM sodium chloride pH 7. The peptide remained soluble in the phosphate buffer at 40°C. for 1 hour and then 55°C. for 1 hour. There was very little product loss, as measured by absorbance at 280 nm, in 0.15M saline buffered with 10 mM acetate at pH 4, 5 or 6. The real time stability study at 4°C showed that product concentration was unchanged. Even the accelerated stability study at 37°C showed that greater than 95% of product concentration was maintained and that only low levels (less than 0.5% at 50 days) of new HPLC peaks accumulated with time at 37°C in the acetate buffered saline formulations. Given the substantial stability exhibited by the Domain III derived peptide as

tested, additional excipients may not be necessary but may be desired to further enhance long-term stability and/or activity.

Numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the foregoing description on the presently preferred embodiments thereof. Consequently the only limitations which should be placed upon the scope of the present invention are those that appear in the appended claims.

10

15

20

25

30

- 2200069

86

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT:
 - (A) NAME: XOMA CORPORATION
 - (B) STREET: 2910 Seventh Street
 - (C) CITY: Berkeley
 - (D) STATE: California
 - (E) COUNTRY: United States of America
 - (F) POSTAL CODE: 94710
- (ii) TITLE OF INVENTION: Anti-Fungal Peptides
- (iii) NUMBER OF SEQUENCES: 206
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
 - (B) STREET: 6300 Sears Tower, 233 South Wacker Drive
 - (C) CITY: Chicago
 - (D) STATE: Illinois
 - (E) COUNTRY: United States of America
 - (F) ZIP: 60606-6402
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/372,105
 - (B) FILING DATE: 13-JAN-95
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/306,473
 - (B) FILING DATE: 15-SEP-94
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/273,540
 - (B) FILING DATE: 11-JUL-94
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/209,762
 - (B) FILING DATE: 11-MAR-94
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/183,222
 - (B) FILING DATE: 14-JAN-94
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/093,202
 - (B) FILING DATE: 15-JUL-93
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/030,644
 - (B) FILING DATE: 12-MAR-93

87

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Borun, Michael F.
- (B) REGISTRATION NUMBER: 25,447
- (C) REFERENCE/DOCKET NUMBER: 27129/10040

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 312/474-6300
- (B) TELEFAX: 312/474-0448
- (C) TELEX: 25-3856

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.5"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Val His Val His Ile Ser Lys Ser Lys Val Gly Trp Leu Ile Gln Leu
1 5 10 15

Phe His Lys Lys Ile Glu
 20

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.11"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Lys Ser Lys Val Trp Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:3:

- 2200069

88

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 29 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.12"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
- | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Val | His | Val | His | Ile | Ser | Lys | Ser | Lys | Val | Gly | Trp | Leu | Ile | Gln |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Leu | Phe | His | Lys | Lys | Ile | Glu | Ser | Ala | Leu | Arg | Asn | Lys | | | |
| | | | 20 | | | | | 25 | | | | | | | |

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.13"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
- | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Ser | Lys | Val | Gly | Trp | Leu | Ile | Gln | Leu | Phe | His | Lys | Lys |
| 1 | | | | 5 | | | | 10 | | | | | |

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 28 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.29"
- (ix) FEATURE:

- 2200069

89

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Lys Ser
1           5           10           15

Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys
          20           25

```

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.31"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Ala Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys
1           5           10

```

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.32"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

Lys Ala Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys
1           5           10

```

(2) INFORMATION FOR SEQ ID NO:8:

90

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.33"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
- | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Ser | Ala | Val | Gly | Trp | Leu | Ile | Gln | Leu | Phe | His | Lys | Lys |
| 1 | | | | 5 | | | | | 10 | | | | |
- (2) INFORMATION FOR SEQ ID NO:9:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.34"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
- | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Ser | Lys | Ala | Gly | Trp | Leu | Ile | Gln | Leu | Phe | His | Lys | Lys |
| 1 | | | | 5 | | | | | 10 | | | | |
- (2) INFORMATION FOR SEQ ID NO:10:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.35"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation

- 2200069

91

/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Lys	Ser	Lys	Val	Ala	Trp	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.36"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Lys	Ser	Lys	Val	Gly	Ala	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.37"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Lys	Ser	Lys	Val	Gly	Trp	Ala	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- 2200069

92

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.38"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Lys Ser Lys Val Gly Trp Leu Ala Gln Leu Phe His Lys Lys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.39"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Lys Ser Lys Val Gly Trp Leu Ile Ala Leu Phe His Lys Lys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.40"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Lys Ser Lys Val Gly Trp Leu Ile Gln Ala Phe His Lys Lys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.41"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Gln	Leu	Ala	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.42"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Gln	Leu	Phe	Ala	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.43"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site

94

- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Ala Lys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.44"

- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Ala
 1 5 10

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.55"

- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Gly Trp Leu Ile Gln Leu Phe His Lys Lys Ile Glu Ser Ala Leu Arg
 1 5 10 15

Asn Lys Met Asn Ser
 20

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:

- 2200069

95

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.82"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Gln	Leu	Trp	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.83"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 10..12
- (D) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 6 is beta-1-naphthyl-substituted"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Lys	Ser	Lys	Val	Gly	Ala	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.85"

96

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Lys Ser Lys Val Leu Trp Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.86"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.87"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Leu Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids

- 2200069

97

(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.91"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.92"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Lys Ser Lys Val Gly Trp Leu Ile Lys Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.94"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

- 2200069

98

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Gln	Leu	Phe	Phe	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.95"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Lys	Ser	Lys	Val	Phe	Trp	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.96"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Gln	Leu	Phe	His	Lys	Phe
1				5					10				

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- 2200069

99

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.97"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Lys Ser Lys Val Lys Trp Leu Ile Gln Leu Phe His Lys Lys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.100"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Lys Ser Lys Val Lys Trp Leu Ile Lys Leu Phe His Lys Lys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.101"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Lys Ser Lys Val Lys Trp Leu Ile Lys Leu Phe Phe Lys Phe Lys Ser
 1 5 10 15

Lys Val Lys Trp Leu Ile Lys Leu Phe Phe Lys Phe

100

20

25

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.104"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Ser	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.106"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Thr	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.107"

- 2200069

101

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Trp Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc feature
- (D) OTHER INFORMATION: "XMP.108"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Trp
1 5 10

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc feature
- (D) OTHER INFORMATION: "XMP.109"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 11
- (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 11 is beta-1-naphthyl-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Ala His Lys Lys

2200069

102

1

5

10

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(D) OTHER INFORMATION: "XMP.110"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 12

(C) OTHER INFORMATION: /label= Substituted-Ala

/note= "Position 12 is beta-1-naphthyl-substituted."

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: C-Terminus

(D) OTHER INFORMATION: /label= Amidation

/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Ala Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(D) OTHER INFORMATION: "XMP.111"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 14

(C) OTHER INFORMATION: /label= Substituted-Ala

/note= "Position 14 is beta-1-naphthyl-substituted."

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: C-Terminus

(D) OTHER INFORMATION: /label= Amidation

/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO:41:

- 2200069

103

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.113"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:
- | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Ser | Lys | Val | Gly | Trp | Leu | Ile | Gln | Phe | Phe | His | Lys | Lys |
| 1 | | | | 5 | | | | | 10 | | | | |
- (2) INFORMATION FOR SEQ ID NO:42:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.116"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: 6
 (C) OTHER INFORMATION: /label= Substituted-Ala
 /note= "Position 6 is beta-1-naphthyl-substituted."
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:
- | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Ser | Lys | Val | Lys | Ala | Leu | Ile | Gln | Leu | Phe | His | Lys | Lys |
| 1 | | | | 5 | | | | | 10 | | | | |
- (2) INFORMATION FOR SEQ ID NO:43:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature

2200069

104

(D) OTHER INFORMATION: "XMP.123"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 9
- (C) OTHER INFORMATION: /label= Substituted-Phe
/note= "The phenylalanine at position 9 is
p-amino-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Phe	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc feature
- (D) OTHER INFORMATION: "XMP.124"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Lys	Ser	Lys	Val	Lys	Trp	Leu	Ile	Gln	Leu	Trp	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc feature
- (D) OTHER INFORMATION: "XMP.125"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

- 2200069

105

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Lys Ser Lys Val Gly Trp Leu Ile Tyr Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.126"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (C) OTHER INFORMATION: /label= D-Trp
/note= "Position 6 is D-tryptophan."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.127"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

Lys Ser Lys Val Gly Phe Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids

106

- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
- (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.128"

- (ix) FEATURE:
- (A) NAME/KEY: Modified-site
 - (B) LOCATION: 6
 - (C) OTHER INFORMATION: /label= D-Phe
/note= "Position 6 is D-phenylalanine."

- (ix) FEATURE:
- (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Lys	Ser	Lys	Val	Gly	Phe	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:49:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
- (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.129"

- (ix) FEATURE:
- (A) NAME/KEY: Modified-site
 - (B) LOCATION: 6
 - (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 6 is D-1-beta-1-naphthyl-substituted."

- (ix) FEATURE:
- (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

Lys	Ser	Lys	Val	Gly	Ala	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:50:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

- 2200069

107

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.130"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 6 is beta-2-naphthyl-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.131"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 6 is D-beta-2-naphthyl-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

108

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.132"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "The alanine at position 6 is
pyridyl-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated" .

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.133"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (C) OTHER INFORMATION: /label= Substituted-Phe
/note= "Position 6 is para-amino-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Lys Ser Lys Val Gly Phe Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.134"

- 2200069

109

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (C) OTHER INFORMATION: /label= Substituted-Phe
/note= "Position 5 is para-amino-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Lys Ser Lys Val Phe Trp Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.135"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Lys Ser Lys Val Gly Lys Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.137"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

Cys Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Cys

- 2200069

110

1

5

10

15

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.138"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

Lys	Ser	Lys	Val	Lys	Phe	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.139"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

Lys	Ser	Lys	Val	Gly	Tyr	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.142"

- 2200069

111

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Gln	Trp	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc feature
- (D) OTHER INFORMATION: "XMP.143"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 10
- (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 10 is beta-1-naphthyl-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Gln	Ala	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc feature
- (D) OTHER INFORMATION: "XMP.144"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "The alanine at position 6 is
cyclohexyl-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site

- 2200069

112

- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:62:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.146"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 12
 - (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 12 is beta-1-naphthyl-substituted."
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 14
 - (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 14 is beta-1-naphthyl-substituted."
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Ala Lys Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO:63:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.148"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 6
 - (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 6 is beta-1-naphthyl-substituted."

- 2200069

113

(ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: 12
 (C) OTHER INFORMATION: /label= Substituted-Ala
 /note= "Position 12 is beta-1-naphthyl-substituted."

(ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

Lys	Ser	Lys	Val	Gly	Ala	Leu	Ile	Gln	Leu	Phe	Ala	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.161"

(ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

Lys	Ser	Lys	Val	Lys	Ala	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.166"

(ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

Lys	Ser	Lys	Val	Gly	Val	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

- 2200069

114

1

5

10

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.222"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6 & 14
- (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Positions 6 and 14 are beta-1-naphthyl-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.223"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6 & 10
- (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Positions 6 & 10 are beta-1-naphthyl-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

Lys Ser Lys Val Gly Ala Leu Ile Gln Ala Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:68:

- 2200069

115

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.224"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: 6
 (C) OTHER INFORMATION: /label= Substituted-Ala
 /note= "Position 6 is beta-1-naphthyl-substituted."
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: 9
 (C) OTHER INFORMATION: /label= Substituted-Phe
 /note= "Position 9 is para-amino-substituted."
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:
- | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Ser | Lys | Val | Gly | Ala | Leu | Ile | Phe | Leu | Phe | His | Lys | Lys |
| 1 | | | | 5 | | | | | 10 | | | | |
- (2) INFORMATION FOR SEQ ID NO:69:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.225"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: 6
 (C) OTHER INFORMATION: /label= Substituted-Ala
 /note= "Position 6 is beta-1-naphthyl-substituted."
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: 5
 (C) OTHER INFORMATION: /label= Substituted-Phe
 /note= "Position 5 is para-amino-substituted."
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation

- 2200069

116

/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

Lys	Ser	Lys	Val	Phe	Ala	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.226"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 6 is beta-1-naphthyl-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

Lys	Ser	Lys	Val	Gly	Ala	Leu	Ile	Gln	Leu	Trp	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.227"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 10 & 14
- (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Positions 10 & 14 are beta-1-naphthyl-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

- 2200069

117

Lys Ser Lys Val Gly Trp Leu Ile Gln Ala Phe His Lys Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO:72:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc feature
 - (D) OTHER INFORMATION: "XMP.228"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 9
 - (C) OTHER INFORMATION: /label= Substituted-Phe
/note= "Position 9 is para-amino-substituted."
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 14
 - (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 14 is beta-1-naphthyl-substituted."
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO:73:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc feature
 - (D) OTHER INFORMATION: "XMP.229"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 5
 - (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 5 is para-amino-substituted."
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 14
 - (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 14 is beta-1-naphthyl-substituted."

- 2200069

118

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

Lys Ser Lys Val Phe Trp Leu Ile Gln Leu Phe His Lys Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO:74:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.230"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 14
- (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 14 is beta-1-naphthyl-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Trp His Lys Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO:75:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.231"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 10 & 12
- (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Positions 10 & 12 are beta-1-naphthyl-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus

2200069

119

(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

Lys Ser Lys Val Gly Trp Leu Ile Gln Ala Phe Ala Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:76:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.232"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 9
(C) OTHER INFORMATION: /label= Substituted-Phe
/note= "Position 9 is para-amino-substituted."

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 12
(C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 12 is beta-1-naphthyl-substituted."

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe Ala Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:77:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.233"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 5
(C) OTHER INFORMATION: /label= Substituted-Phe
/note= "Position 5 is para-amino-substituted."

- 2200069

120

(ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: 12
 (C) OTHER INFORMATION: /label= Substituted-Ala
 /note= "Position 12 is beta-1-naphthyl-substituted."

(ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

Lys Ser Lys Val Phe Trp Leu Ile Gln Leu Phe Ala Lys Lys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:78:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
 (A) NAME/KEY: misc feature
 (D) OTHER INFORMATION: "XMP.234"

(ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: 12
 (C) OTHER INFORMATION: /label= Substituted-Ala
 /note= "Position 12 is beta-1-naphthyl-substituted."

(ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Trp Ala Lys Lys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:79:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
 (A) NAME/KEY: misc feature
 (D) OTHER INFORMATION: "XMP.235"

(ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: 9

= 2200069

121

(C) OTHER INFORMATION: /label= Substituted-Phe
/note= "Position 9 is para-amino-substituted."

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 10
(C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 10 is beta-1-naphthyl-substituted."

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

Lys Ser Lys Val Gly Trp Leu Ile Phe Ala Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:80:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.236"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 5
(C) OTHER INFORMATION: /label= Substituted-Phe
/note= "Position 5 is para-amino-substituted."

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 10
(C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 10 is beta-1-naphthyl-substituted."

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

Lys Ser Lys Val Phe Trp Leu Ile Gln Ala Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:81:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

- 2200069

122

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(D) OTHER INFORMATION: "XMP.237"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 10

(C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 10 is beta-1-naphthyl-substituted."

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: C-Terminus

(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Gln	Ala	Trp	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:82:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(D) OTHER INFORMATION: "XMP.238"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 5

(C) OTHER INFORMATION: /label= Substituted-Phe
/note= "Position 5 is para-amino-substituted."

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 9

(C) OTHER INFORMATION: /label= Substituted-Phe
/note= "Position 9 is para-amino-substituted."

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: C-Terminus

(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

Lys	Ser	Lys	Val	Phe	Trp	Leu	Ile	Phe	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:83:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids

2200069

123

- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.239"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 9
- (C) OTHER INFORMATION: /label= Substituted-Phe
/note= "Position 9 is para-amino-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Phe	Leu	Trp	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:84:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.240"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (C) OTHER INFORMATION: /label= Substituted-Phe
/note= "Position 5 is para-amino-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

Lys	Ser	Lys	Val	Phe	Trp	Leu	Ile	Gln	Leu	Trp	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:85:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

124

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.241"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Leu	Leu	Trp	His	Lys	Lys
1				5						10			

(2) INFORMATION FOR SEQ ID NO:86:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.242"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 6 is D-beta-2-naphthyl-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

Lys	Ser	Lys	Val	Gly	Ala	Leu	Ile	Leu	Leu	Phe	His	Lys	Lys
1				5						10			

(2) INFORMATION FOR SEQ ID NO:87:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.243"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6

2200069

125

(C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 6 is D-beta-2-naphthyl-substituted."

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Trp His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:88:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.244"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 6
(C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 6 is D-beta-2-naphthyl-substituted."

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

Lys Ser Lys Val Gly Ala Leu Ile Leu Leu Trp His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:89:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.249"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

2200069

126

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

Lys Ser Lys Val Gly Gly Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:90:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.250"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

Lys Ser Lys Val Gly Leu Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:91:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.251"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

Lys Ser Lys Val Gly Ile Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:92:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

127

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.252"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /label= D-Ala
/note= "Position 6 is D-alanine"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:93:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.253"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /label= D-Val
/note= "Position 6 is D-valine"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

Lys Ser Lys Val Gly Val Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:94:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.254"

2200069

128

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /label= beta-Ala
/note= "Position 6 is beta-alanine"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:95:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.255"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /label= alpha-aba
/note= "Position 6 is alpha-aminobutyric acid"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

Lys Ser Lys Val Gly Xaa Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:96:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.256"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6

- 2200069

129

(D) OTHER INFORMATION: /label= gaba
/note= "Position 6 is gamma-aminobutyric acid"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

Lys Ser Lys Val Gly Xaa Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:97:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.257"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 6
(D) OTHER INFORMATION: /label= α -methyl-A
/note= "Position 6 is alpha-Methyl-alanine"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:98:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.258"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 6
(D) OTHER INFORMATION: /label= t-butyl-G
/note= "Position 6 is tert-butyl-glycine"

- 2200069

130

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

Lys Ser Lys Val Gly Gly Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:99:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.259"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /label= N-methyl-G
/note= "Position 6 is N-Methyl-glycine"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

Lys Ser Lys Val Gly Gly Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:100:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.260"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /label= N-methyl-V
/note= "Position 6 is N-Methyl-valine"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus

131

(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

Lys Ser Lys Val Gly Val Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:101:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.261"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 6
(D) OTHER INFORMATION: /label= N-methyl-L
/note= "Position 6 is N-Methyl-leucine"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

Lys Ser Lys Val Gly Leu Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:102:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.262"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

Lys Ser Lys Val Gly Trp Leu Ile Asn Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:103:

- 2200069

132

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.263"

- (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

Lys Ser Lys Val Gly Trp Leu Ile Glu Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:104:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.264"

- (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

Lys Ser Lys Val Gly Trp Leu Ile Asp Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:105:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.265"

- (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation

- 2200069

133

/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Arg	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:106:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.266"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

Lys	Ser	Lys	Val	Lys	Val	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:107:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.267"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

Lys	Ser	Lys	Val	Lys	Trp	Ala	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10				

(2) INFORMATION FOR SEQ ID NO:108:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

2200069

134

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.268"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

Lys Ser Lys Val Gly Val Ala Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:109:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.269"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

Lys Ser Lys Val Lys Val Ala Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:110:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.270"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys Lys Ser
1 5 10 15

2200069

135

Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys
 20 25

(2) INFORMATION FOR SEQ ID NO:111:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.271"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Lys Ser
 1 5 10 15

Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys
 20 25

(2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.272"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys Lys Ser
 1 5 10 15

Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys
 20 25

(2) INFORMATION FOR SEQ ID NO:113:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

136

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(D) OTHER INFORMATION: "XMP.273"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: C-Terminus

(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Phe	Leu	Phe	His	Lys	Lys	Lys	Ser
1				5					10					15	

Lys	Val	Gly	Trp	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
			20					25			

(2) INFORMATION FOR SEQ ID NO:114:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(D) OTHER INFORMATION: "XMP.274"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: C-Terminus

(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

Lys	Ser	Lys	Val	Gly	Trp	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys	Lys	Ser
1				5					10					15	

Lys	Val	Gly	Trp	Leu	Ile	Phe	Leu	Phe	His	Lys	Lys
			20					25			

(2) INFORMATION FOR SEQ ID NO:115:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(D) OTHER INFORMATION: "XMP.275"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

- 2200069

137

- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys Lys Ser
 1 5 10 15

Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys
 20 25

(2) INFORMATION FOR SEQ ID NO:116:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.283"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

Lys Ser Lys Val Lys Phe Leu Ile Lys Leu Phe His Lys Lys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:117:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.284"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

Ser Lys Val Lys Trp Leu Ile Gln Leu Phe His Lys Lys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:118:

- 2200069

138

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 12 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (D) OTHER INFORMATION: "XMP.285"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:
- | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Lys | Val | Lys | Trp | Leu | Ile | Gln | Leu | Phe | His | Lys |
| 1 | | | | 5 | | | | | 10 | | |
- (2) INFORMATION FOR SEQ ID NO:119:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 12 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.286"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:
- | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Val | Lys | Trp | Leu | Ile | Gln | Leu | Phe | His | Lys | Lys |
| 1 | | | | 5 | | | | | 10 | | |
- (2) INFORMATION FOR SEQ ID NO:120:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.287"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site

- 2200069

139

- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

Ser Lys Val Lys Trp Leu Ile Gln Leu Phe His
1 5 10

(2) INFORMATION FOR SEQ ID NO:121:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.288"

- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

Lys Val Lys Trp Leu Ile Gln Leu Phe His Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:122:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.289"

- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

Val Lys Trp Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:123:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

- 2200069

140

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.290"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

Ser	Lys	Val	Lys	Trp	Leu	Ile	Gln	Leu	Phe
1			5					10	

(2) INFORMATION FOR SEQ ID NO:124:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.291"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

Lys	Val	Lys	Trp	Leu	Ile	Gln	Leu	Phe	His
1			5					10	

(2) INFORMATION FOR SEQ ID NO:125:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.292"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

Val Lys Trp Leu Ile Gln Leu Phe His Lys

141

1

5

10

(2) INFORMATION FOR SEQ ID NO:126:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.293"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

Lys	Trp	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10

(2) INFORMATION FOR SEQ ID NO:127:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.294"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

Ser	Lys	Val	Lys	Trp	Leu	Ile	Gln	Leu
1			5					

(2) INFORMATION FOR SEQ ID NO:128:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.295"

- 2200069

142

- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

Lys Val Lys Trp Leu Ile Gln Leu Phe
1 5

(2) INFORMATION FOR SEQ ID NO:129:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.296"

- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

Val Lys Trp Leu Ile Gln Leu Phe His
1 5

(2) INFORMATION FOR SEQ ID NO:130:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.297"

- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

Lys Trp Leu Ile Gln Leu Phe His Lys
1 5

(2) INFORMATION FOR SEQ ID NO:131:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids

143

(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.298"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

Trp Leu Ile Gln Leu Phe His Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:132:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.299"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

Ser Lys Val Lys Trp Leu Ile Gln
1 5

(2) INFORMATION FOR SEQ ID NO:133:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.300"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

- 2 2 0 0 0 6 9

144

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

Lys Val Lys Trp Leu Ile Gln Leu
1 5

(2) INFORMATION FOR SEQ ID NO:134:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.301"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

Val Lys Trp Leu Ile Gln Leu Phe
1 5

(2) INFORMATION FOR SEQ ID NO:135:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.302"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

Lys Trp Leu Ile Gln Leu Phe His
1 5

(2) INFORMATION FOR SEQ ID NO:136:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

= 2200069

145

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.303"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

Trp Leu Ile Gln Leu Phe His Lys
1 5

(2) INFORMATION FOR SEQ ID NO:137:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.304"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

Leu Ile Gln Leu Phe His Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:138:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.305"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

Ser Lys Val Lys Trp Leu Ile
1 5

(2) INFORMATION FOR SEQ ID NO:139:

2200069

146

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.306"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:
- Lys Val Lys Trp Leu Ile Gln
1 5
- (2) INFORMATION FOR SEQ ID NO:140:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.307"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:
- Val Lys Trp Leu Ile Gln Leu
1 5
- (2) INFORMATION FOR SEQ ID NO:141:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.308"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation

- 2 2 0 0 0 6 9

147

/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

Lys Trp Leu Ile Gln Leu Phe
1 5

(2) INFORMATION FOR SEQ ID NO:142:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.309"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

Trp Leu Ile Gln Leu Phe His
1 5

(2) INFORMATION FOR SEQ ID NO:143:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.310"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

Leu Ile Gln Leu Phe His Lys
1 5

(2) INFORMATION FOR SEQ ID NO:144:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- 2200069

148

(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.311"

(ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

Ile Gln Leu Phe His Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:145:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 6 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.312"

(ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

Ser Lys Val Lys Trp Leu
1 5

(2) INFORMATION FOR SEQ ID NO:146:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 6 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.313"

(ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

Lys Val Lys Trp Leu Ile
1 5

- 2200069

149

(2) INFORMATION FOR SEQ ID NO:147:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.314"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

Val Lys Trp Leu Ile Gln
1 5

(2) INFORMATION FOR SEQ ID NO:148:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.315"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

Lys Trp Leu Ile Gln Leu
1 5

(2) INFORMATION FOR SEQ ID NO:149:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.316"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site

150

- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

Trp Leu Ile Gln Leu Phe
1 5

(2) INFORMATION FOR SEQ ID NO:150:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.317"

- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

Leu Ile Gln Leu Phe His
1 5

(2) INFORMATION FOR SEQ ID NO:151:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.318"

- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

Ile Gln Leu Phe His Lys
1 5

(2) INFORMATION FOR SEQ ID NO:152:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

- 2 2 0 0 0 6 9

151

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.319"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

Gln Leu Phe His Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:153:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.320"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

Trp Leu Ile Gln Leu
1 5

(2) INFORMATION FOR SEQ ID NO:154:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.321"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

Trp Leu Ile Gln Leu Lys

2200069

152

1

5

(2) INFORMATION FOR SEQ ID NO:155:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.322"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

Trp Leu Ile Gln Leu Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:156:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.323"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

Lys Trp Leu Ile Gln Leu Lys
1 5

(2) INFORMATION FOR SEQ ID NO:157:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.324"

- 2200069

153

- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

Lys Trp Leu Ile Gln Leu Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:158:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 (A) NAME/KEY: misc feature
 (D) OTHER INFORMATION: "XMP.325"

- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

Lys Lys Trp Leu Ile Gln Leu
1 5

(2) INFORMATION FOR SEQ ID NO:159:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 8 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 (A) NAME/KEY: misc feature
 (D) OTHER INFORMATION: "XMP.326"

- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

Lys Lys Trp Leu Ile Gln Leu Lys
1 5

(2) INFORMATION FOR SEQ ID NO:160:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids

154

(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.327"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:

Lys Lys Trp Leu Ile Gln Leu Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:161:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.330"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:

Trp Leu Ile Gln
1

(2) INFORMATION FOR SEQ ID NO:162:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.331"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 1
(D) OTHER INFORMATION: /label= Acetylated
/note= "Position 1 is acetylated"

- 2200069

155

- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:

Lys Lys Trp Leu Ile Gln Leu Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:163:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.332"

- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: 1-9
 (D) OTHER INFORMATION: /label= D-Amino Acids
 /note= "Positions 1-9 are D-amino acids"

- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

Lys Lys Leu Gln Ile Leu Trp Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:164:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.333"

- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: 1
 (D) OTHER INFORMATION: /label= D-Lys
 /note= "Position 1 is D-lysine"

- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus

156

(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:

Lys Lys Trp Leu Ile Gln Leu Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:165:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.334"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 1
(D) OTHER INFORMATION: /label= D-Pro
/note= "Position 1 is D-proline"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:

Pro Lys Trp Leu Ile Gln Leu Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:166:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.335"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:

Pro Lys Trp Leu Ile Gln Leu Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:167:

- 2200069

157

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.336"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:
- Arg Arg Trp Leu Ile Gln Leu Arg Arg
1 5
- (2) INFORMATION FOR SEQ ID NO:168:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.337"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:
- His His Trp Leu Ile Gln Leu His His
1 5
- (2) INFORMATION FOR SEQ ID NO:169:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.338"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: 1, 2, 8 & 9
 (D) OTHER INFORMATION: /label= Orn

- 2200069

158

/note= "Positions 1, 2, 8 & 9 are Ornithine"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:

Xaa Xaa Trp Leu Ile Gln Leu Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:170:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.339"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1, 2, 8 & 9
- (D) OTHER INFORMATION: /label= Dbu
/note= "Positions 1, 2, 8 & 9 are Diaminobutyric acid"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

Xaa Xaa Trp Leu Ile Gln Leu Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:171:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.340"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1, 2, 8 & 9
- (C) OTHER INFORMATION: /label= Substituted-Phe
/note= "Positions 1, 2, 8 & 9 are para-amino-substituted."

(ix) FEATURE:

159

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:

Phe Phe Trp Leu Ile Gln Leu Phe Phe
1 5

(2) INFORMATION FOR SEQ ID NO:172:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.341"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 1, 2, 8 & 9
 - (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "The alanine at positions 1, 2, 8 & 9 is
pyridyl-substituted."
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:

Ala Ala Trp Leu Ile Gln Leu Ala Ala
1 5

(2) INFORMATION FOR SEQ ID NO:173:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.342"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 1, 2, 8 & 9
 - (D) OTHER INFORMATION: /label= D-Lys
/note= "Positions 1, 2, 8 & 9 are D-lysine"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus

- 2 2 0 0 0 6 9

160

(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:

Lys Lys Trp Leu Ile Gln Leu Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:174:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.343"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:

Lys Lys Val Leu Ile Gln Leu Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:175:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "XMP.344"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: C-Terminus
(D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:

Lys Lys Trp Ala Ile Gln Leu Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:176:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

- 2 2 0 0 0 6 9

161

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.345"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

Lys Lys Trp Leu Ile Gln Ala Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:177:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.346"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (C) OTHER INFORMATION: /label= Substituted-Phe
/note= "The phenylalanine at position 3 is
p-amino-substituted."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:

Lys Lys Phe Leu Ile Gln Leu Lys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:178:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.347"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site

162

- (B) LOCATION: 3
- (C) OTHER INFORMATION: /label= Substituted-Ala
/note= "Position 3 is D-beta-2-naphthyl-substituted."

- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

Lys Lys Ala Leu Ile Leu Leu Lys Lys
1 5

- (2) INFORMATION FOR SEQ ID NO:179:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.348"

- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

Lys Lys Lys Trp Leu Ile Gln Leu Lys Lys
1 5 10

- (2) INFORMATION FOR SEQ ID NO:180:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.349"

- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

Lys Lys Trp Leu Ile Gln Leu Lys Lys Lys
1 5 10

163

(2) INFORMATION FOR SEQ ID NO:181:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.350"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

Lys Lys Lys Trp Leu Ile Gln Leu Lys Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:182:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.351"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

Lys Lys Trp Leu Ile Gln Leu Phe Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:183:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.352"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site

- 2200069

164

- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

Lys Lys Trp Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:184:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.353"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:

Pro Trp Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:185:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.354"

- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 1
 - (D) OTHER INFORMATION: /label= Acetylated
/note= "Position 1 is acetylated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

Pro Trp Leu Ile Gln Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:186:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.355"

- 2200069

165

- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:
- Pro Trp Leu Ile Gln Leu Phe His Lys Lys
1 5 10
- (2) INFORMATION FOR SEQ ID NO:187:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.356"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: 1
 (D) OTHER INFORMATION: /label= Acetylated
 /note= "Position 1 is acetylated"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:
- Pro Trp Leu Ile Gln Leu Phe His Lys Lys
1 5 10
- (2) INFORMATION FOR SEQ ID NO:188:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "XMP.357"
- (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:
- Lys Trp Leu Ile Gln Leu Phe His Lys Pro

- 2200069

166

1

5

10

(2) INFORMATION FOR SEQ ID NO:189:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.358"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:

Lys	Lys	Trp	Leu	Ile	Gln	Leu	Phe	His	Lys	Pro
1				5					10	

(2) INFORMATION FOR SEQ ID NO:190:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.359"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (C) OTHER INFORMATION: /label= D-Cys
/note= "Position 1 is D-cysteine."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:

Cys	Trp	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5				10	

(2) INFORMATION FOR SEQ ID NO:191:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: circular

- 2200069

167

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.360"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 & 9
- (C) OTHER INFORMATION: /label= D-Lys
/note= "Positions 1 & 9 are D-lysine."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (C) OTHER INFORMATION: /label= D-Cys
/note= "Position 2 is D-cysteine."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

Lys Cys Leu Ile Gln Leu Phe Cys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:192:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.361"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 & 9
- (C) OTHER INFORMATION: /label= D-Lys
/note= "Positions 1 & 9 are D-lysine."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:

Lys Cys Leu Ile Gln Leu Phe Cys Lys
1 5

(2) INFORMATION FOR SEQ ID NO:193:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids

- 2200069

168

- (B) TYPE: amino acid
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.362"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1 & 11
- (C) OTHER INFORMATION: /label= D-Lys
/note= "Positions 1 & 11 are D-lysine."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:

Lys	Lys	Cys	Leu	Ile	Gln	Leu	Phe	Cys	Lys	Lys
1				5					10	

(2) INFORMATION FOR SEQ ID NO:194:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.363"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1, 9 & 10
- (C) OTHER INFORMATION: /label= D-Lys
/note= "Positions 1, 9 & 10 are D-lysine."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (C) OTHER INFORMATION: /label= D-Trp
/note= "Position 2 is D-tryptophan."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:

Lys	Trp	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10

(2) INFORMATION FOR SEQ ID NO:195:

169

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.364"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 1
 - (D) OTHER INFORMATION: /label= Acetylated
/note= "Position 1 is acetylated"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 1, 9 & 10
 - (C) OTHER INFORMATION: /label= D-Lys
/note= "Positions 1, 9 & 10 are D-lysine."
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 2
 - (C) OTHER INFORMATION: /label= D-Trp
/note= "Position 2 is D-tryptophan."
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:

Lys	Trp	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10
- (2) INFORMATION FOR SEQ ID NO:196:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: peptide
 - (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.365"
 - (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 1-10
 - (D) OTHER INFORMATION: /label= D-Amino Acids
/note= "Positions 1-10 are D-amino acids"
 - (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation

- 2200069

170

/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:

Lys	Trp	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10

(2) INFORMATION FOR SEQ ID NO:197:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc feature
- (D) OTHER INFORMATION: "XMP.366"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /label= Acetylated
/note= "Position 1 is acetylated"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1-10
- (D) OTHER INFORMATION: /label= D-Amino Acids
/note= "Positions 1-10 are D-amino acids"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:

Lys	Trp	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys
1				5					10

(2) INFORMATION FOR SEQ ID NO:198:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc feature
- (D) OTHER INFORMATION: "XMP.367"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1-10
- (D) OTHER INFORMATION: /label= D-Amino Acids
/note= "Positions 1-10 are D-amino acids"

(ix) FEATURE:

171

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:

Lys Lys His Phe Leu Gln Ile Leu Trp Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:199:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.368"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 1
 - (D) OTHER INFORMATION: /label= Acetylated
/note= "Position 1 is acetylated"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 1-10
 - (D) OTHER INFORMATION: /label= D-Amino Acids
/note= "Positions 1-10 are D-amino acids"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: C-Terminus
 - (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:

Lys Lys His Phe Leu Gln Ile Leu Trp Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:200:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (D) OTHER INFORMATION: "XMP.369"
- (ix) FEATURE:
 - (A) NAME/KEY: Modified-site
 - (B) LOCATION: 5
 - (D) OTHER INFORMATION: /label= Orn

- 2200069

172

/note= "Position 5 is Ornithine"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:

Lys	Trp	Leu	Ile	Xaa	Leu	Phe	His	Lys	Lys
1				5					10

(2) INFORMATION FOR SEQ ID NO:201:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.370"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: /label= Orn
/note= "Position 5 is Ornithine"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /label= Acetylated
/note= "Position 1 is acetylated"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:

Lys	Trp	Leu	Ile	Xaa	Leu	Phe	His	Lys	Lys
1				5					10

(2) INFORMATION FOR SEQ ID NO:202:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.371"

(ix) FEATURE:

- 2200069

173

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: /label= Dbu
/note= "Position 5 is Diaminobutyric acid"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:

Lys Trp Leu Ile Xaa Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:203:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (D) OTHER INFORMATION: "XMP.372"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: /label= Dbu
/note= "Position 5 is Diaminobutyric acid"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /label= Acetylated
/note= "Position 1 is acetylated"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: C-Terminus
- (D) OTHER INFORMATION: /label= Amidation
/note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:

Lys Trp Leu Ile Xaa Leu Phe His Lys Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:204:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: misc_feature

- 2200069

174

(D) OTHER INFORMATION: "XMP.373"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
 (B) LOCATION: 1
 (D) OTHER INFORMATION: /label= Acetylated
 /note= "Position 1 is acetylated"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
 (B) LOCATION: C-Terminus
 (D) OTHER INFORMATION: /label= Amidation
 /note= "The C-Terminus is Amidated"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:

Lys Trp Leu Ile Gln Leu Phe His Lys Lys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:205:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1813 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION: 31..1491

(ix) FEATURE:

(A) NAME/KEY: mat_peptide
 (B) LOCATION: 124..1491

(ix) FEATURE:

(A) NAME/KEY: misc_feature
 (D) OTHER INFORMATION: "rBPI"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:

CAGGCCTTGA GGTTTTGGCA GCTCTGGAGG ATG AGA GAG AAC ATG GCC AGG GGC	54
Met Arg Glu Asn Met Ala Arg Gly	
-31 -30 -25	
CCT TGC AAC GCG CCG AGA TGG GTG TCC CTG ATG GTG CTC GTC GCC ATA	102
Pro Cys Asn Ala Pro Arg Trp Val Ser Leu Met Val Leu Val Ala Ile	
-20 -15 -10	
GGC ACC GCC GTG ACA GCG GCC GTC AAC CCT GGC GTC GTG GTC AGG ATC	150
Gly Thr Ala Val Thr Ala Ala Val Asn Pro Gly Val Val Val Arg Ile	
-5 1 5	
TCC CAG AAG GGC CTG GAC TAC GCC AGC CAG CAG GGG ACG GCC GCT CTG	198
Ser Gln Lys Gly Leu Asp Tyr Ala Ser Gln Gln Gly Thr Ala Ala Leu	
10 15 20 25	
CAG AAG GAG CTG AAG AGG ATC AAG ATT CCT GAC TAC TCA GAC AGC TTT	246
Gln Lys Glu Leu Lys Arg Ile Lys Ile Pro Asp Tyr Ser Asp Ser Phe	
30 35 40	

- 2200069

175

AAG	ATC	AAG	CAT	CTT	GGG	AAG	GGG	CAT	TAT	AGC	TTC	TAC	AGC	ATG	GAC	294
Lys	Ile	Lys	His	Leu	Gly	Lys	Gly	His	Tyr	Ser	Phe	Tyr	Ser	Met	Asp	
			45					50					55			
ATC	CGT	GAA	TTC	CAG	CTT	CCC	AGT	TCC	CAG	ATA	AGC	ATG	GTG	CCC	AAT	342
Ile	Arg	Glu	Phe	Gln	Leu	Pro	Ser	Ser	Gln	Ile	Ser	Met	Val	Pro	Asn	
		60					65					70				
GTG	GGC	CTT	AAG	TTC	TCC	ATC	AGC	AAC	GCC	AAT	ATC	AAG	ATC	AGC	GGG	390
Val	Gly	Leu	Lys	Phe	Ser	Ile	Ser	Asn	Ala	Asn	Ile	Lys	Ile	Ser	Gly	
	75					80					85					
AAA	TGG	AAG	GCA	CAA	AAG	AGA	TTC	TTA	AAA	ATG	AGC	GGC	AAT	TTT	GAC	438
Lys	Trp	Lys	Ala	Gln	Lys	Arg	Phe	Leu	Lys	Met	Ser	Gly	Asn	Phe	Asp	
90					95					100					105	
CTG	AGC	ATA	GAA	GGC	ATG	TCC	ATT	TCG	GCT	GAT	CTG	AAG	CTG	GGC	AGT	486
Leu	Ser	Ile	Glu	Gly	Met	Ser	Ile	Ser	Ala	Asp	Leu	Lys	Leu	Gly	Ser	
			110						115					120		
AAC	CCC	ACG	TCA	GGC	AAG	CCC	ACC	ATC	ACC	TGC	TCC	AGC	TGC	AGC	AGC	534
Asn	Pro	Thr	Ser	Gly	Lys	Pro	Thr	Ile	Thr	Cys	Ser	Ser	Cys	Ser	Ser	
			125					130					135			
CAC	ATC	AAC	AGT	GTC	CAC	GTG	CAC	ATC	TCA	AAG	AGC	AAA	GTC	GGG	TGG	582
His	Ile	Asn	Ser	Val	His	Val	His	Ile	Ser	Lys	Ser	Lys	Val	Gly	Trp	
		140					145					150				
CTG	ATC	CAA	CTC	TTC	CAC	AAA	AAA	ATT	GAG	TCT	GCG	CTT	CGA	AAC	AAG	630
Leu	Ile	Gln	Leu	Phe	His	Lys	Lys	Ile	Glu	Ser	Ala	Leu	Arg	Asn	Lys	
	155					160					165					
ATG	AAC	AGC	CAG	GTC	TGC	GAG	AAA	GTG	ACC	AAT	TCT	GTA	TCC	TCC	AAG	678
Met	Asn	Ser	Gln	Val	Cys	Glu	Lys	Val	Thr	Asn	Ser	Val	Ser	Ser	Lys	
170					175					180					185	
CTG	CAA	CCT	TAT	TTC	CAG	ACT	CTG	CCA	GTA	ATG	ACC	AAA	ATA	GAT	TCT	726
Leu	Gln	Pro	Tyr	Phe	Gln	Thr	Leu	Pro	Val	Met	Thr	Lys	Ile	Asp	Ser	
			190						195					200		
GTG	GCT	GGA	ATC	AAC	TAT	GGT	CTG	GTG	GCA	CCT	CCA	GCA	ACC	ACG	GCT	774
Val	Ala	Gly	Ile	Asn	Tyr	Gly	Leu	Val	Ala	Pro	Pro	Ala	Thr	Thr	Ala	
			205					210					215			
GAG	ACC	CTG	GAT	GTA	CAG	ATG	AAG	GGG	GAG	TTT	TAC	AGT	GAG	AAC	CAC	822
Glu	Thr	Leu	Asp	Val	Gln	Met	Lys	Gly	Glu	Phe	Tyr	Ser	Glu	Asn	His	
		220					225					230				
CAC	AAT	CCA	CCT	CCC	TTT	GCT	CCA	CCA	GTG	ATG	GAG	TTT	CCC	GCT	GCC	870
His	Asn	Pro	Pro	Pro	Phe	Ala	Pro	Pro	Val	Met	Glu	Phe	Pro	Ala	Ala	
	235					240					245					
CAT	GAC	CGC	ATG	GTA	TAC	CTG	GGC	CTC	TCA	GAC	TAC	TTC	TTC	AAC	ACA	918
His	Asp	Arg	Met	Val	Tyr	Leu	Gly	Leu	Ser	Asp	Tyr	Phe	Phe	Asn	Thr	
250					255					260					265	
GCC	GGG	CTT	GTA	TAC	CAA	GAG	GCT	GGG	GTC	TTG	AAG	ATG	ACC	CTT	AGA	966
Ala	Gly	Leu	Val	Tyr	Gln	Glu	Ala	Gly	Val	Leu	Lys	Met	Thr	Leu	Arg	
			270					275						280		
GAT	GAC	ATG	ATT	CCA	AAG	GAG	TCC	AAA	TTT	CGA	CTG	ACA	ACC	AAG	TTC	1014
Asp	Asp	Met	Ile	Pro	Lys	Glu	Ser	Lys	Phe	Arg	Leu	Thr	Thr	Lys	Phe	
			285					290						295		

- 2200069

176

TTT	GGA	ACC	TTC	CTA	CCT	GAG	GTG	GCC	AAG	AAG	TTT	CCC	AAC	ATG	AAG	1062
Phe	Gly	Thr	Phe	Leu	Pro	Glu	Val	Ala	Lys	Lys	Phe	Pro	Asn	Met	Lys	
		300					305					310				
ATA	CAG	ATC	CAT	GTC	TCA	GCC	TCC	ACC	CCG	CCA	CAC	CTG	TCT	GTG	CAG	1110
Ile	Gln	Ile	His	Val	Ser	Ala	Ser	Thr	Pro	Pro	His	Leu	Ser	Val	Gln	
		315					320					325				
CCC	ACC	GGC	CTT	ACC	TTC	TAC	CCT	GCC	GTG	GAT	GTC	CAG	GCC	TTT	GCC	1158
Pro	Thr	Gly	Leu	Thr	Phe	Tyr	Pro	Ala	Val	Asp	Val	Gln	Ala	Phe	Ala	
		330					335				340				345	
GTC	CTC	CCC	AAC	TCC	TCC	CTG	GCT	TCC	CTC	TTC	CTG	ATT	GGC	ATG	CAC	1206
Val	Leu	Pro	Asn	Ser	Ser	Leu	Ala	Ser	Leu	Phe	Leu	Ile	Gly	Met	His	
				350					355					360		
ACA	ACT	GGT	TCC	ATG	GAG	GTC	AGC	GCC	GAG	TCC	AAC	AGG	CTT	GTT	GGA	1254
Thr	Thr	Gly	Ser	Met	Glu	Val	Ser	Ala	Glu	Ser	Asn	Arg	Leu	Val	Gly	
			365					370					375			
GAG	CTC	AAG	CTG	GAT	AGG	CTG	CTC	CTG	GAA	CTG	AAG	CAC	TCA	AAT	ATT	1302
Glu	Leu	Lys	Leu	Asp	Arg	Leu	Leu	Leu	Glu	Leu	Lys	His	Ser	Asn	Ile	
		380					385					390				
GGC	CCC	TTC	CCG	GTT	GAA	TTG	CTG	CAG	GAT	ATC	ATG	AAC	TAC	ATT	GTA	1350
Gly	Pro	Phe	Pro	Val	Glu	Leu	Leu	Gln	Asp	Ile	Met	Asn	Tyr	Ile	Val	
		395					400				405					
CCC	ATT	CTT	GTG	CTG	CCC	AGG	GTT	AAC	GAG	AAA	CTA	CAG	AAA	GGC	TTC	1398
Pro	Ile	Leu	Val	Leu	Pro	Arg	Val	Asn	Glu	Lys	Leu	Gln	Lys	Gly	Phe	
		410				415				420				425		
CCT	CTC	CCG	ACG	CCG	GCC	AGA	GTC	CAG	CTC	TAC	AAC	GTA	GTG	CTT	CAG	1446
Pro	Leu	Pro	Thr	Pro	Ala	Arg	Val	Gln	Leu	Tyr	Asn	Val	Val	Leu	Gln	
				430				435						440		
CCT	CAC	CAG	AAC	TTC	CTG	CTG	TTC	GGT	GCA	GAC	GTT	GTC	TAT	AAA		1491
Pro	His	Gln	Asn	Phe	Leu	Leu	Phe	Gly	Ala	Asp	Val	Val	Tyr	Lys		
			445					450					455			
TGAAGGCACC	AGGGGTGCCG	GGGGCTGTCA	GCCGCACCTG	TTCCTGATGG	GCTGTGGGGC											1551
ACCGGCTGCC	TTTCCCCAGG	GAATCCTCTC	CAGATCTTAA	CCAAGAGCCC	CTTGCAAAC											1611
TCTTCGACTC	AGATTCAGAA	ATGATCTAAA	CACGAGGAAA	CATTATTCAT	TGGAAAAGTG											1671
CATGGTGTGT	ATTTTAGGGA	TTATGAGCTT	CTTTCAAGGG	CTAAGGCTGC	AGAGATATTT											1731
CCTCCAGGAA	TCGTGTTTCA	ATTGTAACCA	AGAAATTTCC	ATTTGTGCTT	CATGAAAAAA											1791
AACTTCTGGT	TTTTTTCATG	TG														1813

(2) INFORMATION FOR SEQ ID NO:206:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 487 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:

2200069

177

Met Arg Glu Asn Met Ala Arg Gly Pro Cys Asn Ala Pro Arg Trp Val
 -31 -30 -25 -20
 Ser Leu Met Val Leu Val Ala Ile Gly Thr Ala Val Thr Ala Ala Val
 -15 -10 -5 1
 Asn Pro Gly Val Val Val Arg Ile Ser Gln Lys Gly Leu Asp Tyr Ala
 5 10 15
 Ser Gln Gln Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lys
 20 25 30
 Ile Pro Asp Tyr Ser Asp Ser Phe Lys Ile Lys His Leu Gly Lys Gly
 35 40 45
 His Tyr Ser Phe Tyr Ser Met Asp Ile Arg Glu Phe Gln Leu Pro Ser
 50 55 60 65
 Ser Gln Ile Ser Met Val Pro Asn Val Gly Leu Lys Phe Ser Ile Ser
 70 75 80
 Asn Ala Asn Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe
 85 90 95
 Leu Lys Met Ser Gly Asn Phe Asp Leu Ser Ile Glu Gly Met Ser Ile
 100 105 110
 Ser Ala Asp Leu Lys Leu Gly Ser Asn Pro Thr Ser Gly Lys Pro Thr
 115 120 125
 Ile Thr Cys Ser Ser Cys Ser Ser His Ile Asn Ser Val His Val His
 130 135 140 145
 Ile Ser Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys
 150 155 160
 Ile Glu Ser Ala Leu Arg Asn Lys Met Asn Ser Gln Val Cys Glu Lys
 165 170 175
 Val Thr Asn Ser Val Ser Ser Lys Leu Gln Pro Tyr Phe Gln Thr Leu
 180 185 190
 Pro Val Met Thr Lys Ile Asp Ser Val Ala Gly Ile Asn Tyr Gly Leu
 195 200 205
 Val Ala Pro Pro Ala Thr Thr Ala Glu Thr Leu Asp Val Gln Met Lys
 210 215 220 225
 Gly Glu Phe Tyr Ser Glu Asn His His Asn Pro Pro Pro Phe Ala Pro
 230 235 240
 Pro Val Met Glu Phe Pro Ala Ala His Asp Arg Met Val Tyr Leu Gly
 245 250 255
 Leu Ser Asp Tyr Phe Phe Asn Thr Ala Gly Leu Val Tyr Gln Glu Ala
 260 265 270
 Gly Val Leu Lys Met Thr Leu Arg Asp Asp Met Ile Pro Lys Glu Ser
 275 280 285
 Lys Phe Arg Leu Thr Thr Lys Phe Phe Gly Thr Phe Leu Pro Glu Val
 290 295 300 305

- 2200069

178

Ala Lys Lys Phe Pro Asn Met Lys Ile Gln Ile His Val Ser Ala Ser
310 315 320

Thr Pro Pro His Leu Ser Val Gln Pro Thr Gly Leu Thr Phe Tyr Pro
325 330 335

Ala Val Asp Val Gln Ala Phe Ala Val Leu Pro Asn Ser Ser Leu Ala
340 345 350

Ser Leu Phe Leu Ile Gly Met His Thr Thr Gly Ser Met Glu Val Ser
355 360 365

Ala Glu Ser Asn Arg Leu Val Gly Glu Leu Lys Leu Asp Arg Leu Leu
370 375 380 385

Leu Glu Leu Lys His Ser Asn Ile Gly Pro Phe Pro Val Glu Leu Leu
390 395 400

Gln Asp Ile Met Asn Tyr Ile Val Pro Ile Leu Val Leu Pro Arg Val
405 410 415

Asn Glu Lys Leu Gln Lys Gly Phe Pro Leu Pro Thr Pro Ala Arg Val
420 425 430

Gln Leu Tyr Asn Val Val Leu Gln Pro His Gln Asn Phe Leu Leu Phe
435 440 445

Gly Ala Asp Val Val Tyr Lys
450 455

WHAT IS CLAIMED IS:

1. An antifungal peptide having from seven to twelve amino acids comprising:

5 (a) a core sequence of amino acids selected from the group consisting of LIQL, IQLF, WLIQL, LIQLF and WLIQLF; and

(b) one or more cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion thereof.

10 2. An antifungal peptide having from seven to nine amino acids comprising:

(a) a core sequence of amino acids selected from the group consisting of LIQL and IQLF; and

15 (b) at least two cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion thereof.

3. An antifungal peptide having from eight to ten amino acids comprising:

(a) a core sequence of amino acids selected from the group consisting of LIQLF and WLIQLF; and

20 (b) at least two cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion thereof.

4. An antifungal peptide having from nine to twelve amino acids comprising:

25 (a) a core sequence of amino acids selected from the group consisting of WLIQLF; and

(b) at least three cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion thereof.

5 5. An antifungal peptide according to claim 1, 2, 3 or 4 selected from the group consisting of the peptides of SEQ ID NOS: 118-137 (XMP.285-304), 140-144 (XMP.307-311), 155-160 (XMP.322-327), 166-170 (XMP.335-339), 174-177 (XMP.343-346), 179-184 (XMP.348-353), 186 (XMP.355) and 188-190 (XMP.357-359).

6. An antifungal peptide according to claim 1, 2, 3 or 4 having one or more D-isomer amino acids.

7. An antifungal peptide according to claim 6 selected from the group consisting of the peptides of SEQ ID NOS: 164 (XMP.333), 165 (XMP.334), 173 (XMP.342), 194 (XMP.363) and 196 (XMP.365).

8. An antifungal peptide according to claim 6 wherein said core sequence amino acids comprise D-isomer amino acids in reverse sequence order.

20 9. An antifungal peptide according to claim 8 having the amino acid sequence set out in SEQ ID NOS:163 (XMP.332) and 198 (XMP.367).

10. An antifungal peptide according to claim 1, 2, 3 or 4 wherein the amino terminal amino acid residue is acetylated.

11. An antifungal peptide according to claim 10 selected from the group consisting of the peptides of SEQ ID NOS: 162 (XMP.331), 185

(XMP.354), 187 (XMP.356), 195 (XMP.364), 199 (XMP.368) and 204 (XMP.373).

5 12. A cyclic antifungal peptide according to claim 1, 3 or 4.

10 13. A cyclic antifungal peptide according to claim 8 selected from the group consisting of SEQ ID NOS: 191, 192 and 193.

15 14. An antifungal peptide selected from the group consisting of peptides of SEQ ID NOS: 116-117 (XMP.283-284), 132 (XMP.299), 138-139 (XMP.305-306), 145-154 (XMP.312-321) and 200-203 (XMP.369-372).

20 15. A pharmaceutical composition comprising an antifungal peptide according to any one of claims 1 through 14 and a pharmaceutically acceptable diluent, adjuvant or carrier.

25 16. An in vitro method for killing or inhibiting replication of fungi comprising contacting the fungi with an antifungal peptide according to any one of claims 1 through 14.

30 17. Use of an antifungal peptide according to any one of claims 1 through 14 for the manufacture of a medicament for the treatment of a fungal infection alone.

35 18. Use of an antifungal peptide according to any one of claims 1 through 14 in combination with another antifungal agent for the manufacture of a medicament for the treatment of a fungal infection.

19. Use of an antifungal peptide according to any one of claims 1 to 14 for the manufacture of a medicament for the co-treatment or sequential treatment of a fungal infection with another antifungal agent.

20. A use according to any one of claims 17 to 19, wherein the fungal infection involves a fungal species selected from the group consisting of *Candida*, *Aspergillosis*, and *Cryptococcus* species.

5

21. A use according to claim 20, wherein the *Candida* species is selected from the group consisting of *C. albicans*, *C. glabrata*, *C. krusei*, *C. lusitaniae*, *C. parapsilosis* and *C. tropicalis*.

10

22. A use according to any one of claims 17 to 19, wherein the peptide is suitable for administration topically, intravenously, orally or as an aerosol.


15

23. A use according to claim 19, wherein the other antifungal agent is a non-peptide antifungal agent.

24. An antifungal peptide according to any one of claims 1 to 14 for use as a medicament.


1/10

Figure 1




2/10

Figure 2A



3/10


Figure 2B



2200069


4/10

Figure 3



5/10


FIGURE 4



- 2200069

6/10

FIGURE 5



7/10

FIGURE 6





FIGURE 7




Days After 1.98x10⁵ Candida Administration

- 2200069

9/10

Figure 8



10/10

Figure 9

